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ABSTRACT 
 
SELECTIVE INHIBITION OF HISTONE DEACETYLASES 
 
Nicholas J. Porter 
Dr. David W. Christianson 
 
 Reversible lysine acetylation serves as a critical regulatory pathway for diverse cellular pro-
cesses. As a result, the dysregulation of proteinaceous acetyl-L-lysine hydrolysis is connected to 
severe medical conditions including neurological disorders, immune dysfunction, and cancer. Inhi-
bition of the enzymes responsible for catalyzing this reaction, histone deacetylases (HDACs), has 
demonstrated promising results as a route to clinical intervention in many of these diseases. Of the 
18 known HDACs, 11 are metal-dependent enzymes that have similar mechanisms and each reg-
ulates the function of numerous protein substrates in vivo. This frustrates the design of small mol-
ecules targeting a single isozyme, meaning that modern FDA-approved HDAC inhibitors exhibit 
various side effects that make them less-than-optimal for broad clinical application. 
 This thesis describes the characterization of HDAC–inhibitor complexes by crystallog-
raphy, supported by thermodynamic and enzymological measurements, focusing on a class I en-
zyme, HDAC8, and a class IIb enzyme, HDAC6. Structural analysis of complexes with inhibitors 
exhibiting class- or isozyme-selective activity has illuminated the structural underpinnings of iso-
zyme-selective HDAC inhibition. For instance, irreversible inhibition of class I HDACs by the 
epoxyketone-based inhibitor trapoxin A is due to the conformation of the epoxide group, rather 
than a long-presumed covalent modification in the active site. With regard to HDAC6, selective 
vi 
 
hydroxamates exhibit an unusual monodentate metal-coordination mode mediated by steric inter-
actions at the protein surface. HDAC6 is also predisposed to be inhibited by hydroxamates over 
other isozymes due to a unique entropic gain associated with inhibitor binding. Finally, mercapto-
acetamides serve as an alternative, non-genotoxic zinc-binding group that can exploit subtle mech-
anistic differences between isozymes. Taken together, these studies have constructed a framework 
for the design of selective HDAC inhibitors for better-targeted therapeutics.  
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Chapter 1 | Background 
Portions reprinted from Porter, N. J.; Christianson, D.W. Curr. Opin. Struct. Biol. 2019, 59, 9-18. 
1.1 | Post-translational modifications 
  Critical biological processes are often regulated by diverse and dynamic reversible covalent 
modifications to protein structures that tune their function in response to changes in cellular con-
ditions.1,2 These post-translational modifications (PTMs) include methylation, acetylation/acyla-
tion, phosphorylation, glycosylation, sumoylation, ubiquitination, and a number of other less-
common modifications (Figure 1.1).1–4 These reactions alter the chemical properties of specific 
protein residues, resulting in either a gain or loss of function when this new functionality is intro-
duced into a protein structure. 
  This is exemplified by the acetylation of lysine side chains on the N-terminal tails of his-
tone proteins. Histone heterooctamers wrapped in 147 base pairs of DNA form the nucleosome, 
the core unit of chromatin responsible for the compaction of the genome.5,6 One interaction gov-
erning nucleosome formation is charge complementarity between positively charged lysines and 
arginines on histone tails and the negatively charged DNA backbone.7,8 Acetylation of these lysine 
residues removes their positive charge, weakening this interaction and assisting in the activation 
of gene transcription.9 Combined with lysine and arginine methylation, phosphorylation of serine 
and threonine residues, and other modifications on these tails, these PTMs constitute the “histone 
code” that regulates dynamic transitions between transcriptionally active and silent chromatin 
states.10,11 These are referred to as epigenetic modifications, meaning they control gene expression 
without altering the genes themselves, and instead are heritable through cellular replication.12,13 
However, while many PTMs were first identified on histone tails, the biological utility of these 
functional “switches” goes far beyond genetic regulation.14 
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Figure 1.1 | Common post-translational modifications  
Structures of modifying groups are shown in red. The N-terminus of histone H3.1 (blue) from a 
crystal structure of the human nucleosome (3AFA) is used as an example. 
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1.2 | The Acetylome 
  The reversible acetylation of lysine side chains on the surfaces of enzymes and other pro-
teins comprises a vital regulatory strategy in myriad cellular processes such as transcription, the 
cell cycle, and metabolism (Figure 1.2).15–18 At present, the acetylome encompasses nearly 40,000 
unique protein acetylation sites as classified in the PhosphoSitePlus database.4 Accordingly, acet-
ylation rivals phosphorylation as a ubiquitous chemical modification in the regulation of protein 
function.19  
  The chemistry of lysine acetylation requires “writers” – acetyl transferases that utilize ace-
tyl-CoA as a co-substrate,20,21 and “erasers” – deacetylases that catalyze the hydrolysis of acetyl-
lysine to yield lysine and acetate.22 With their identification rooted in Allfrey’s pioneering discov-
ery of histone acetylation,9 lysine deacetylases are historically referred to as histone deacetylases 
(HDACs). However, this name belies the wider function of these enzymes in processing both 
histone and non-histone protein substrates. Moreover, certain HDACs are not lysine deacetylases, 
but instead are lysine fatty-acid deacylases;23,24 others process non-protein substrates through their 
function as polyamine deacetylases.25  
  The HDACs are particularly important as targets for therapeutic intervention in the treat-
ment of cancer, neurodegenerative disease, and other disorders.26–28 To date, four different inhib-
itors of metal-dependent HDACs are approved in the US for cancer chemotherapy, and each 
inhibitor targets the active site Zn2+ ion. Vorinostat,29 Belinostat,30 and Panobinostat31 contain 
hydroxamic acid moieties that chelate Zn2+, and Romidepsin is a cyclic depsipeptide bearing a 
pendant thiol group that coordinates to Zn2+.32,33 These inhibitors are relatively non-selective, i.e., 
they generally do not exhibit significant preference for the inhibition of one particular HDAC  
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Figure 1.2 | Representation of the acetylome 
(a) General scheme for the reversible acetylation of an L-lysine residue in protein X. (b) Repre-
sentative sample of proteins (grey & colored squares) regulated by acetylation in diverse cellular 
processes. Adapted from Choudhary et al. Science 2009, 325, 834-840. Reprinted with permission 
from AAAS. 
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isozyme or another, so off-target side effects can result from their use.26 Accordingly, the devel-
opment of isozyme-selective HDAC inhibitors is a priority for current drug design efforts.  
1.3 | Arginase-deacetylase fold 
  Metal-dependent HDACs adopt an a/b fold first observed in the binuclear manganese 
metalloenzyme arginase,34 which was subsequently observed in the histone deacetylase-like protein 
from Aquifex aeolicus.35 This structural and evolutionary relationship was unexpected, since these 
two enzymes share insignificant amino acid sequence identity (15%). Even so, the Zn2+ binding 
site of the HDACs is conserved as the Mn2+B site of the arginases.36,37 Thus, metal binding stoi-
chiometry and selectivity in the arginase-deacetylase family diverged from a common metalloen-
zyme ancestor. 
Recent phylogenetic analysis indicates 12 clades in the arginase-deacetylase family (Figure 
1.3).25 The arginase family38 also includes agmatinases, ureohydrolases, formiminoglutamases, and 
even pseudo-arginases that lack metal binding sites, such as the arginase-like protein of unknown 
function in Trypanosoma brucei.39 In addition to the HDAC isozymes, the deacetylase family also 
includes bacterial polyamine deacetylases, acetoin utilization proteins, and pseudo-deacetylases of 
unknown chemical function.40 The closest relationship between the arginases and deacetylases de-
picted in Figure 1.3 is found between human agmatinase and the pseudo-deacetylase domain of 
guinea pig HDAC10, which share 19% amino acid sequence identity.  
1.4 | Metal-dependent HDAC isozymes 
  Since the discovery of the first mammalian HDAC,41 11 metal-dependent HDACs have 
been identified and classified through phylogenetic analysis:42 the class I isozymes HDAC1, 
HDAC2, HDAC3, and HDAC8; the class IIa isozymes HDAC4, HDAC5, HDAC7, and  
6 
 
 
Figure 1.3 | Arginase-deacetylase family of proteins 
Unrooted phylogenetic tree indicates 12 clades: arginases, pseudo-deacetylases (YArg), 
formiminoglutamases (FIGase) and ureohydrolases, yeast Hos3 homologues, bacterial acetylpoly-
amine amidohydrolases (APAH), bacterial histone deacetylases-like amidohydrolases (HDAH), 
class II HDACs, class I HDACs, bacterial acetoin utilization proteins (AcuC), class IV HDACs, 
uncharacterized protein family UPF0489, and pseudo-deacetylases (YDAC). Individual proteins, 
species, and UniProt accession numbers are listed in Supplementary Table 3 from ref. 25. Reprinted 
from Hai, Y. et al. Nat. Commun. 2017, 8, 15368. (Creative Commons Attribution 4.0 Interna-
tional License).  
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HDAC9; the class IIb isozymes HDAC6 and HDAC10; and the sole class IV isozyme, HDAC11 
(Figure 1.4). X-ray crystal structures of metal-dependent HDACs reveal conservation of the a/b 
arginase-deacetylase fold: HDAC1,43,44 HDAC2,45 HDAC3,46 HDAC4,47 HDAC6,48,49 
HDAC7,50 HDAC8,51,52 and HDAC10.25 Crystal structures of HDAC isozymes illuminate crit-
ical molecular features of biological function and inhibition.  
  Among the class I HDACs, HDAC8 is the only enzyme that exerts activity in both the 
nucleus and the cytosol.53 This isozyme has been shown to act upon numerous proteins in vivo 
that are involved in actin assembly,54,55 transcription,56 mitosis,57 and apoptotic regulation.58 How-
ever, analysis of the acetylome following the selective inhibition of HDAC8 reveals even more 
potential substrates involved in these and other processes including splicing, protein folding, and 
other enzymes that mediate post-translational modifications.59 The origin of this broad substrate 
profile of HDAC8 remains poorly understood. The most well-characterized substrate is structural 
maintenance of chromosomes protein 3 (SMC3), which is involved in the formation of the cohe-
sion complex during mitosis.57 Single point mutations to HDAC8 can perturb this enzyme-sub-
strate interaction to cause Cornelia de Lange syndrome (CdLS), a congenital malformation dis-
order.60–62  
The class IIb enzyme HDAC6 plays a role in cytoskeleton maintenance,63 cellular traffick-
ing,64 and misfolded protein response.65 It is the only HDAC enzyme bearing two separate lysine 
deacetylase domains, one of which primarily acts upon acetylated a-tubulin while the biological 
function of the other is currently unknown.66,67 However, recent studies have revealed that this 
domain of unknown function is capable of deacetylating C-terminal acetyllysine in vitro.48 The 
loss of HDAC6 function results in neuronal resistance to amyloid-b-mediated blockage of mito-
chondrial trafficking, so HDAC6 inhibition is thought to be a viable route to the treatment of  
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Figure 1.4 | Phylogenetic classes of histone deacetylases 
Histone deacetylases subdivided into phylogenetic classes with representations of protein localiza-
tion, size, deficiency phenotype, and location of the lysine deacetylase (KDAC), polyamine 
deacetylase (PDAC), pseudo-deacetylase (YDAC), or lysine deacylase (KDAX) domain(s). The 
number of residues in the human proteins is shown to the lower right of each enzyme’s domain 
architecture. The class III sirtuins bear an orthogonal fold and mechanism and are not within the 
scope of this work. The class I HDAC8 and class IIb HDAC6 enzymes are highlighted and serve 
as the focus of this thesis. 
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neurological disorders.68,69 The requirement of HDAC6 activity for oncogenic tumorigenesis also 
indicates that its inhibition may provide a viable route to clinical intervention in certain cancers.70 
1.5 | Mechanism of amide bond hydrolysis 
  A catalytic mechanism for the hydrolysis of acetyllysine by a metal-dependent deacetylase 
was first proposed with the crystal structure determination of the bacterial histone deacetylase-like 
protein.35 Subsequent studies refined this mechanistic proposal, based in large part on structural 
and enzymological studies of HDAC8 (Figure 1.5). In the precatalytic Michaelis complex, the 
scissile carbonyl group of acetyllysine coordinates to Zn2+ and accepts a hydrogen bond from the 
phenol oxygen of Y306. A zinc-carbonyl interaction in the Michaelis complex is consistent with 
the metal-dependent variation of KM for HDAC8 against assay substrates when Fe2+ and Co2+ are 
substituted for Zn2+,71 as well as the crystal structures of intact substrates bound to the Y306F and 
H143A HDAC8 variants.72,73 Y306 may undergo induced-fit conformational changes between 
“out” and “in” orientations to accommodate substrate binding, as indicated by computational and 
experimental studies of HDAC8 and related deacetylases.47,61,74,75  
Both metal coordination and hydrogen bond interactions are required to fully activate the 
acetyllysine carbonyl group for nucleophilic attack by a Zn2+-bound water molecule. Enzymolog-
ical studies of wild-type HDAC8 and site-specific variants indicate that H143 serves as a general 
base to assist Zn2+ in activating the nucleophilic water molecule; subsequently, H143 serves as a 
general acid to protonate the leaving amino group, thereby enabling the collapse of the tetrahedral 
intermediate to yield lysine and acetate.76,77 The imidazolium side chain of H142 serves as an 
electrostatic catalyst, remaining protonated throughout the catalytic cycle. Both H142 and H143 
hydrogen bond with the Zn2+-bound water molecule, thereby ensuring its optimal orientation for 
nucleophilic attack. In class I isozymes, product acetate may depart through a “backdoor” tunnel  
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Figure 1.5 | Mechanism of metal-dependent histone deacetylase 8 (HDAC8) 
Enzymological and structural measurements are consistent with H143 serving as a single general 
base-general acid, while H142 remains in the positively charged imidazolium state to serve as an 
electrostatic catalyst. However, hydrogen bond differences for the tandem histidine pair in other 
HDAC isozymes may allow for separate general base-general acid functions in these histidine res-
idues. Structural evidence suggests that, in HDAC6, H573 serves as a general base and H574 serves 
as a general acid.48 
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during dissociation of the enzyme-product complex.78 This tunnel may also accommodate the fatty 
acid product in the weak fatty acid deacylase activity measured for HDAC8.79  
Binding interactions of the tetrahedral intermediate and its flanking transition states have 
been visualized through the study of reactive substrate analogues that, upon binding in active site, 
undergo a chemical reaction that mimics the first step of catalysis. Specifically, consider the cyclic 
tetrapeptide HC toxin (Figure 1.6), a naturally occuring inhibitor of HDACs from Helmin-
thosporium carbonum.80,81 HC toxin contains a non-proteinogenic amino acid bearing an a,b-
epoxyketone amino acid, (2S,9S)-2-amino-8-oxo-9,10-epoxydecanoic acid (L-Aoe). The ketone 
carbonyl group of the L-Aoe side chain is isosteric with the amide carbonyl group of acetyl-L-
lysine, the HDAC substrate. The crystal structure of catalytic domain 2 from Danio rerio 
(zebrafish) HDAC6 in complex with HC toxin shows that the ketone carbonyl undergoes nucle-
ophilic attack to yield a tetrahedral gem-diolate that mimics the tetrahedral intermediate in catal-
ysis.48 The presumed oxyanion of the gem-diolate coordinates to Zn2+ and accepts a hydrogen 
bond from Y745, and the hydroxyl group of the gem-diolate forms hydrogen bonds with H573 
and H574 (Figure 1.6).  
Intriguingly, cocrystallization of H574A HDAC6 with an acetyllysine-containing sub-
strate yields an electron density map showing tetrahedral instead of planar electron density for the 
scissile amide moiety, suggesting that the actual tetrahedral intermediate is trapped in the active 
site.48 This suggests that the intact histidine, H573, serves as the general base in catalysis, while 
H574 serves only as a general acid, rather than as both base and acid as observed for the equivalent 
residue, H143, in HDAC8. Since the tetrahedral intermediate cannot collapse without a proton 
donor to the leaving amino group, the loss of general acid H574 results in the dead-end formation 
of the tetrahedral intermediate in much the same way as the tetrahedral gem-diolate of HC Toxin  
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Figure 1.6 | HDAC6–HC toxin complex 
Polder omit map for HDAC toxin bound to catalytic domain 2 of Danio rerio HDAC6 determined 
at 1.73 Å resolution (PDB 5EFJ) in which the a,b-epoxyketone side chain binds as a gem-diolate 
in the reversible enzyme-inhibitor complex. The backbone NH group of L-Aoe donates a hydrogen 
bond to S531, a key determinant of isozyme-substrate recognition.  
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is formed and stabilized in the HDAC6 active site. Crystal structures of HDAC4,47 HDAC6,48 
and HDAC1025 complexed with a-trifluoromethylketones similarly reveal the binding of the 
gem-diolate form of these inhibitors in deacetylase active sites.  
As indicated in Figure 1.5, key catalytic residues in the active sites of most HDACs are the 
tandem histidine dyad, a catalytic tyrosine, and the Zn2+ ion. However, in class IIa HDACs (4, 5, 
7, and 9), the catalytic tyrosine is substituted with a histidine, and deacetylase activity is signifi-
cantly compromised as a result.82 Even so, robust lysine deacetylase activity of HDAC4 and 
HDAC7 can be restored by histidine-to-tyrosine substitutions.47,50,82 The biological significance 
of this activity difference is unclear. The active sites of most zinc hydrolases contain an electrophile 
in addition to the Zn2+ ion that helps polarize the scissile amide carbonyl, as first noted for the 
prototypical zinc hydrolases thermolysin and carboxypeptidase A.83,84 Possibly, the electrophilic 
histidine in the active sites of class IIa HDACs confers an alternative substrate specificity that is 
yet to be discovered.47 
1.6 | Structural basis of substrate specificity 
  X-ray crystal structures of HDAC isozymes complexed with substrates or substrate ana-
logues reveal the molecular basis of substrate recognition. As lysine deacetylases, HDAC6 and 
HDAC8 catalyze the hydrolysis of acetyllysine residues contained in polypeptide and protein sub-
strates, and the active site of each enzyme consists of a concave molecular surface surrounding a 
narrow cavity that accommodates the scissile acetyllysine side chain.48,51,52 Crystal structures of 
H143A HDAC8 and Y306F HDAC8 complexed with the p53-derived assay substrate Ac-Arg-
His-Aly-Aly-AMC (Aly = acetyllysine, AMC = aminomethylcoumarin) show that the backbone 
NH groups of the scissile acetyllysine residue (boldface) and the aminomethylcoumarin moiety at 
the +1 position donate hydrogen bonds to the carboxylate side chain of D101 (Figure 1.7a).72,73  
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Figure 1.7 | Substrate binding to HDAC isozymes 
(a) Superposition of substrate complexes with Y306F HDAC8 (blue; PDB 2V5W) and H143A 
HDAC8 (grey; PDB 3EWF) demonstrates that the scissile acetyllysine carbonyl is activated by the 
Zn2+ ion and Y306. (b) Superposition of substrate complexes with Y745F HDAC6 (dark green; 
PDB 5EFK) and H574A HDAC6 (light green; PDB 5EFN) reveals similar activation, but the 
tetrahedral intermediate is present in the complex with H574A HDAC6, suggesting that this his-
tidine serves as only the general acid in catalysis. (c) A tetrahedral gem-diolate is observed for the 
trifluoromethylketone analogue of N8-acetylspermidine bound to HDAC10 (PDB 5TD7) in 
which a 310-helix (purple) imposes steric constraints on the active site to confer acetylpolyamine 
substrate specificity.  
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Dual hydrogen bond interactions with D101 suggest that a proline residue at the +1 position of 
the substrate cannot be accommodated by HDAC8, and this has been confirmed experimentally.48 
No other hydrogen bonds are observed between the concave active site surface of HDAC8 and 
main chain atoms for residues in the –3 to –1 positions of the bound substrate; the guanidinium 
group of the arginine residue at the –3 position forms hydrogen bonds with the backbone carbonyl 
of I94 or the carboxylate group of E148, or makes no hydrogen bonds at all in several crystal 
structures.72,73 The lack of strong enzyme-substrate hydrogen bond specificity presumably ensures 
broad specificity for flanking amino acid sequences in protein substrates. Although no structural 
information is available with regard to peptide substrate binding at the +2 position or beyond, 
there is enzymological evidence for an exosite that recognizes the basic sequence KRHR at the +4 
to +7 positions of a substrate derived from the N-terminal tail of the histone H4 protein.85 
In contrast with HDAC8, crystal structures of HDAC6 complexed with two different as-
say substrates, the a-tubulin-derived peptide Ac-Ser-Asp-Aly-AMC and the histone H4-derived 
peptide Ac-Arg-Gly-Aly-AMC, show that only a single hydrogen bond is made between the 
backbone NH group of the scissile acetyllysine residue and S531 (Figure 1.7b); the corresponding 
hydrogen bond is similarly observed between S531 and the NH group of the a,b-epoxyketone 
residue of HC Toxin.48 Accordingly, HDAC6 substrates can accommodate proline residues at the 
+1 position. In the HDAC6-substrate complexes, the peptide segments preceding the scissile 
acetyllysine residues are disordered and hence not fully modeled in the refined crystal structures.48 
However, the backbone carbonyl of the aspartate or glycine residue at the –1 positions of these 
substrates hydrogen bonds with N530. Here, too, minimal hydrogen bonding with main chain or 
side chain atoms enables broad specificity for flanking amino acid sequences in protein substrates.  
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In contrast with HDAC6 and HDAC8, the crystal structure of HDAC10 reveals an active 
site cleft sterically constricted by a 310-helix containing the highly conserved P(E,A)CE motif 
(Figure 1.7c).25,86 Consequently, peptide substrates cannot bind easily in the active site of 
HDAC10 due to the long, narrow active site cleft. Instead, the active site of HDAC10 accom-
modates long, slender polyamine substrates, exhibiting optimal catalytic efficiency for the deacety-
lation of N8-acetylspermidine. A conserved gatekeeper in the HDAC10 active site, E274, ensures 
electrostatic recognition of the positively charged secondary amino group of N8-acetylspermidine. 
Conserved glutamate and aspartate residues across the protein surface additionally contribute to 
the molecular recognition of the cationic substrate.25 HDAC10 appears to be the long-sought 
cytosolic N8-acetylspermidine deacetylase for which cellular activity was discovered more than 40 
years ago.87,88 
1.7 | Regulation by corepressors 
  Several metal-dependent HDACs function in multi-protein regulatory complexes. For ex-
ample, crystal structures of HDAC1 and HDAC3 complexed with corepressor proteins that acti-
vate catalysis reveal significant protein-protein interactions that sandwich inositol tetraphosphate 
at the interface.43,44,46 Corepressor binding buttresses the L1 loop flanking the deacetylase active 
site, which reduces enzyme surface dynamics.46 Inositol tetraphosphate interacts with a conserved 
arginine side chain on the L6 loop, which forms one wall of the active site.44 Mutation of this 
arginine in the HDAC3-SMRT corepressor complex results in a dramatic loss of enzyme activ-
ity,43 suggesting that this interaction is vital for activation of these class I HDACs.  
  Molecular dynamics simulations of HDAC3 reveal conformational mobility for the cata-
lytic tyrosine in the active site, which adopts the “out” conformation in the absence of corepressor 
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and the catalytically-required “in” conformation upon the binding of corepressor.75 Similar con-
formational mobility has been observed for this residue in molecular dynamics studies of 
HDAC861 and in X-ray crystallographic studies of a bacterial polyamine deacetylase.74 Conforma-
tional mobility of the catalytic tyrosine in HDAC active sites is facilitated by its location in a 
conserved glycine-rich loop.89 Conformational control of the catalytic tyrosine in the class I 
HDAC active site by deacetylase-activating domains of corepressor proteins represents a simple 
molecular strategy for the regulation of deacetylase activity in multi-protein complexes. 
Notably, HDAC8 is the only class I enzyme that does not require a corepressor for optimal 
activity due to structural differences in the L1 and L6 loops that allow the enzyme to more readily 
adopt an active conformation without steric persuasion from a corepressor protein. Even so, active 
site loops in HDAC8 can adopt alternative conformations even as they accommodate derivatives 
of the cyclic tetrapeptide inhibitor Largazole.90 Inhibition of HDAC8 results in the upregulated 
acetylation of many different proteins in vivo,59 suggesting that the more flexible surface loops of 
this isozyme may allow it to recognize a variety of substrates throughout the cell. 
1.8 | Inhibitor binding and isozyme selectivity 
  Given that HDACs are validated targets for therapeutic intervention in the treatment of 
cancer and other diseases, X-ray crystal structures provide valuable guidance for drug design. A 
key feature of an HDAC inhibitor is the functional group that coordinates to the active site Zn2+ 
ion. The hydroxamate group is most commonly utilized and is found in three out of four of the 
currently-approved HDAC-targeted drugs (Figure 1.8a).26–28 However, the hydroxamate group 
can be mutagenic due to degradation via the Lossen rearrangement, which generates a highly 
reactive isocyanate capable of alkylating cellular components (Figure 1.8b).91 This chemical reac-
tivity can limit the utility of hydroxamate-containing drugs.  
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Figure 1.8 | HDAC inhibitors 
(a) FDA-approved hydroxamate-based HDAC inhibitors for clinical use in cancer chemotherapy. 
(b) Hydroxamate genotoxicity stems from their degradation through the Lossen rearrangement to 
the electrophilic isocyanate moiety. (c) Romidepsin is currently FDA-approved for cancer chemo-
therapy and can be activated by reduction of an intramolecular disulfide linkage. The marine natural 
product Largazole is structurally similar to Romidepsin and is activated by thioester hydrolysis. (d) 
Ideal tetrahedral coordination of the active site Zn2+ ion by the thiolate side chain of Largazole is 
observed in the complex with HDAC8 (PDB 3RQD), in which the thiolate also accepts a hydro-
gen bond from Y306.  
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  Macrocyclic peptides and depsipeptides comprise a fascinating class of HDAC inhibitors. 
These natural products contain pendant side chains that mimic the scissile acetyllysine side chain 
of an HDAC substrate. Romidepsin is a depsipeptide drug that, upon reduction of an intramo-
lecular disulfide linkage, yields a side chain bearing a thiol group that coordinates to the active site 
Zn2+ ion. While the crystal structure of an HDAC-Romidepsin complex has not yet been re-
ported, the crystal structures of HDAC8 complexed with Largazole and its synthetic analogues, 
which are structurally similar to Romidepsin, have been reported (Figure 1.8c,d).90,92  
  Other functional groups targeting Zn2+ coordination in HDAC active sites include a-tri-
fluoromethylketones, which bind as Zn2+-bound gem-diolates in the active sites of HDAC4,47 
HDAC6,48 and HDAC10 (Figure 1.7c),25 and benzamides that chelate the Zn2+ ion of HDAC2 
through the anilide nitrogen and amide carbonyl groups.45 There are numerous opportunities for 
new HDAC inhibitor designs incorporating alternative metal-binding groups, such as those ex-
emplified in a recent review on bioinorganic fragment-based drug discovery.93 
1.9 | Focus of Thesis 
  The work presented herein focuses on the study and structural characterization of inhibitor 
binding to the class I enzyme HDAC8 as well as catalytic domain 2 (the primarily active domain) 
of the class IIb enzyme HDAC6. The ultimate goal of this work is to illuminate the chemical 
details underlying class- or isozyme-selective inhibition. In these studies, HDAC8 serves as a fac-
ile model for class I enzymes due to its activity in isolation (i.e. HDAC8 does not require a core-
pressor for activity as do HDACs 1, 2, and 3). Catalytic domain 2 from Danio rerio (zebrafish) 
HDAC6 serves as a more readily-crystallizable ortholog of the human enzyme in which all resi-
dues in and around the active site are generally conserved. 
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  With regard to HDAC8, this thesis describes the complex with a microbial cyclic tetrapep-
tide inhibitor, trapoxin A, which bears the unusual a,b-epoxyketone as the metal-binding group 
as found in HC toxin. This inhibitor exhibits irreversible inhibition against class I HDACs but 
can readily dissociate from class II enzymes. Structural analysis reveals that the origin of this irre-
versible inhibition lies in steric interactions of the epoxide group with a groove in the active site 
cavity coupled with hydration of the ketone moiety to a gem-diolate. This revises the long-stand-
ing hypothesis that irreversibility was due to the covalent modification of a nucleophile only found 
in the active sites of class I HDACs. The tight-binding nature of this inhibitor in the absence of 
covalent enzyme-inhibitor attachments invites new lines of inquiry in the design of potent mole-
cules targeting the class I enzymes. 
  The majority of the presented work focuses on the characterization of the structural un-
derpinnings of HDAC6-selective inhibition. Medicinal chemistry has identified a wide variety of 
HDAC6 inhibitors which exhibit 10-1000–fold selectivity, most of which are hydroxamate-based 
inhibitors bearing short, rigid aromatic linkers and large, sterically bulky capping groups. Intri-
guingly, many of these inhibitors are shown to exploit an unusual monodentate metal-coordina-
tion mode that is accessible in the shallower active site cavity of HDAC6 relative to other HDAC 
isozymes. This binding mode is largely controlled by steric interactions between the capping group 
and loops at the active sit surface, especially the L1 loop. Fascinatingly, even small cyclohydrox-
amates lacking capping groups are selective HDAC6 inhibitors due to a favorable entropic gain 
upon binding to this isozyme, which is not observed for other HDACs. An entropic penalty is 
incurred upon binding to other isozymes for these and other hydroxamate compounds, suggesting 
that HDAC6 is predisposed to inhibition by such molecules. Finally, the characterization of a 
complex between HDAC6 and a selective mercaptoacetamide-based inhibitor reveals that this 
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zinc-binding group exhibits different interactions when bound to class I and class IIb enzymes. 
Additional hydrogen bonds are observed that suggest that this warhead is capable of targeting 
subtle mechanistic differences between HDAC isozymes. 
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Chapter 2 | Class I HDAC Inhibition by Trapoxin A 
Work presented here is reprinted from Porter, N.J.; Christianson, D.W. ACS Chem. Biol. 2017, 12, 
2281-2286. 
 
2.1 | Introduction 
  Macrocyclic HDAC inhibitors (HDACis) are comprised of rigid scaffolds to which a 
Zn2+-coordinating functional group is attached through a linker that is the approximate length of 
a lysine side chain. This metal-binding group can vary; the cyclic depsipeptides romidepsin94,95 and 
largazole92,96 bear a pendant thiol group while the cyclic tetrapeptides apicidin97 and HC toxin80 
bear ethylketone or a,b-epoxyketone moieties, respectively (Figure 2.1). Notably, Romidepsin is 
the only non-hydroxamate HDACi approved by the Food and Drug Administration (FDA) for 
clinical use for the treatment of cutaneous and peripheral T-cell lymphoma.98 As such, under-
standing the mode of inhibition by cyclic tetrapeptides bearing unique metal-coordination groups 
is of vital importance for the development of effective therapies. 
  Trapoxin A, first isolated from the microbial parasite Helicoma ambiens, is a macrocyclic 
tetrapeptide HDAC inhibitor with the amino acid sequence cyclo-[L-Phe–L-Phe–D-hPro–L-
Aoe] (hPro = homoproline, also known as pipecolic acid; L-Aoe = (2S,9S)-2-amino-8-oxo-9,10-
epoxydecanoic acid)99. The a,b-epoxyketone moiety of the L-Aoe side chain serves as the Zn2+-
coordinating group, and its ketone carbonyl group is isosteric with the scissile carbonyl of the 
HDAC substrate acetyl-L-lysine (Figure 2.1). Trapoxin A is proposed to act as an irreversible 
inhibitor of class I HDACs100,101 and was used for the first isolation of HDAC1 from the nuclear 
extracts of human Jurkat T cells.41 The epoxide moiety of the L-Aoe side chain was thought to 
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react with the nucleophilic side chain of an active site residue; however, a covalent enzyme–inhib-
itor complex was not observable by SDS-PAGE/autoradiography.101 Curiously, although trapoxin 
A was found to irreversibly inhibit HDAC1, a class I enzyme, it displayed reversible inhibition 
against the class IIb enzyme HDAC6.102 The molecular basis of these activity differences has re-
mained unclear in the absence of structural data. 
 To address this gap in knowledge, we determined the first X-ray crystal structure of 
trapoxin A complexed with a class I histone deacetylase, HDAC8, at 1.24 Å resolution. These 
data indicate that the irreversible inhibition observed for trapoxin A against class I HDACs does 
not stem from a covalent modification in the active site. This is corroborated by isothermal titra-
tion calorimetry and mass spectrometry experiments. Instead, structural features of the metal-co-
ordinating group and positioning of the epoxide ring within the active site binding pocket con-
tribute to an exceptionally tight enzyme-inhibitor complex in which trapoxin A is effectively 
locked into the enzyme active site. 
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Figure 2.1 | Cyclic peptide HDAC inhibitors 
Microbial cyclic peptide HDAC inhibitors bearing a,b-epoxyketone (trapoxin A & HC toxin), 
thiol (Romidepsin & Largazole), and ethylketone (apicidin) zinc binding groups that mimic the 
scissile amide linkage in HDAC substrate acetyl-L-lysine. 
  
25 
 
2.2 | Materials & Methods 
2.2.1 – Chemical Reagents 
  Chemicals used in buffers and crystallization were purchased from Fischer, Sigma-Aldrich, 
or Hampton Research and used without further purification. Each polymerase chain reaction 
(PCR) was performed using PfuUltra High-Fidelity DNA polymerase (Agilent Technologies). 
Restriction enzyme Ssp1 was purchased from New England Biolabs and used according to the 
manufacturer’s instructions. Oligonucleotides for cloning and mutagenesis were synthesized by 
Integrated DNA Technologies. All DNA sequences were confirmed at the Genomics Analysis 
Core, Perelman School of Medicine, University of Pennsylvania. Escherichia coli strain DH5a 
(Invitrogen) was used for cloning and plasmid preparation. Trapoxin A and apicidin were pur-
chased from Sigma-Aldrich at ³98% purity. Coumarinyl peptide substrates were purchased from 
Enzo Life Sciences. 
2.2.2 – Protein Expression and Purification 
  To generate the HDAC8 construct used for crystallization, the codon-optimized HDAC8 
gene was amplified from the previously described HDAC8-His6-pET20b construct73 (primers: 
forward – 5’-TACTTCCAATCCAATGCAGA-CTCTGGGCAGTCTCTG-3’; reverse – 5’-
TTATCCACTTCCAATGTTATTACCTCATTTCAGGTTGCC). This was cloned into 
the pET His6 MBP TEV LIC cloning vector (1M), a gift from Scott Gradia (University of Cal-
ifornia, Berkeley; Addgene plasmid #29656), in-frame with a TEV-cleavable N-terminal His-
MBP-tag (MBP; maltose binding protein) using ligation independent cloning. 
  The HDAC8 construct bearing a C-terminal hexahistidine tag (HDAC8His) was used for 
experiments except where otherwise noted. Wild-type and mutant HDAC8His expression was per-
formed as previously described73 with minor modifications. Briefly, 50 mL starting cultures were 
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grown overnight in Lysogeny Broth (LB) in the presence of 100 µg/mL ampicillin. These were 
inoculated into 12 ´ 1 L M9 minimal media with 100 µg/mL ampicillin at 37˚C. When the OD600 
reached ~1.0, expression was induced at 18˚C for wild-type and 16˚C for mutants by adding 200 
µM ZnCl2 (Hampton Research) and 100 µM isopropyl-b-thiogalactopyranoside. After expression 
for 18-21 hours, cells were pelleted via centrifugation and stored at -80˚C until purification. 
HDAC8His was purified as previously described.73 All protein was concentrated over 10 kDa mo-
lecular weight cut-off (MWCO) centrifugal filters (Millipore) to 8-20 mg/mL. Protein concen-
trations were determined from the absorbance at 280 nm using the molar extinction coefficient 
50,240 M-1cm-1. Aliquots were flash-frozen in liquid nitrogen and stored at -80˚C. 
 The His-MBP-TEV-HDAC8 construct, consisting of Ser-Asn followed by residues 8-
374 of human HDAC8 and thus designated “HDAC8374”, was used for crystallography. 
HDAC8374 was expressed in the same manner as HDAC8His, the only difference being that 50 
µg/mL kanamycin was used in place of 100 µg/mL ampicillin. This construct was purified using 
a modified version of the protocol described for similar constructs of HDAC6.48 Briefly, cells were 
resuspended and lysed by sonication in loading buffer [50 mM Tris (pH 8.0), 300 mM KCl, 5% 
glycerol, 1 mM TCEP] and applied to amylose resin (New England Biolabs). Protein was eluted 
with 10 mM maltose and incubated with recombinant His-tobacco etch virus protease (TEVP) 
at 4˚C overnight. The cleaved protein was run over Ni(II)-NTA resin (Qiagen). His-MBP and 
His-TEVP were eluted with 400 mM imidazole and removal of these proteins was verified using 
SDS-PAGE. If separation was less than satisfactory, flow-through fractions were then subjected 
to a second Ni(II)-NTA column. HDAC8374-containing fractions were then concentrated by cen-
trifugation to 5-10 mL and loaded onto a HiLoad SuperDex 200 column (GE Healthcare) in size 
exclusion buffer [50 mM Tris (pH 8.0), 150 mM KCl, 5% glycerol, 1 mM TCEP]. Purified 
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HDAC8374 was concentrated to 10-20 mg/mL and flash-frozen in liquid nitrogen for storage at -
80˚C. 
  The HDAC8374 construct appeared to exhibit somewhat lower activity than HDAC8His 
with specific activities of 1030 ± 10 and 1530 ± 30 (nmol P)•(µmol E)-1•min-1, respectively. How-
ever, isothermal titration calorimetry (ITC) measurements of trapoxin A binding to both HDAC8 
constructs reveal identical dissociation constants (Kd = 3 ± 1 nM) but lower N values for the same 
concentration of enzyme, suggesting that HDAC8374 may be slightly Zn2+ deficient following pu-
rification. 
2.2.3 – C153S HDAC8His Mutagenesis 
  The C153S mutation was introduced in the HDAC8-His6-pET20b construct using Quik-
change site-directed mutagenesis (Agilent Technologies). The forward primer sequence used was 
5’-GCTTCTGGTTTCTCTTACCTGAACGATGCC-3’ and the reverse primer sequence 
was 5’-GGCATCGTTCAGGTAAGAGAAACCAGAAGC-3’. The PCR product was se-
quenced at the Genomics Analysis Core to confirm mutation. The mutant was expressed and 
purified using the same protocol outlined for HDAC8His presented above. Plasmids for H142A 
and Y306F HDAC8His were utilized as in previously reported studies.77 
2.2.4 – Crystallization 
  The HDAC8374-trapoxin A complex was cocrystallized in a sitting drop using the vapor 
diffusion method at 4˚C. HDAC8374 (5 mg/mL) was incubated with 400 µM trapoxin A in size 
exclusion buffer with 1% dimethyl sulfoxide (DMSO) at room temperature for 1 hour. A 350 nL 
drop was then combined with 350 nL of precipitant solution (35% dioxane) and equilibrated 
against an 80 µL reservoir of precipitant solution. Large triangular prism crystals were observed 
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after 3 days. Crystal were immersed in a cryoprotectant solution comprised of mother liquor sup-
plemented with 15% ethylene glycol before being flash-cooled in liquid nitrogen. 
2.2.5 – Crystal Structure Determination 
  X-ray diffraction data were collected at the Stanford Synchrotron Radiation Lightsource 
(SSRL), beamline 9-2. Data reduction and integration were carried out using iMosflm103 and 
scaled using Aimless in the CCP4 suite of programs.104 Molecular replacement was executed using 
the atomic coordinates of H143A HDAC8 (PDB ID: 3EWF)73 without ligands as a search model 
in Phaser.105 Coot was used to build and adjust the model in the electron density map, and refine-
ment was performed with PHENIX.106,107 Trapoxin A, dioxane, ethylene glycol, and water mole-
cules were added in later stages of refinement. Occasional spurious electron density peaks were 
present that could not be unambiguously modeled by solvent or other additives present during 
crystallization, so these were left uninterpreted. The quality of the final model was evaluated with 
MolProbity and PROCHECK.108,109 Multiple conformations were observed for E23, S43, V82, 
C102, T105, D147, E148, S150, L55, S190, M196, S204, S215, L235, K239, Q242, S246, C275, 
M279, S328, D333, T349, S351, and C352. Electron density was ambiguous or absent for the 
D87-I94 segment in the L2 loop as well as part or all of the side chains of L14, V15, K58, K60, 
and E106, so these were omitted from the final model. Crystallographic and refinement statistics 
are presented in Table 2.1. 
2.2.6 – Inhibitor Reversibility Dialysis Assay 
  To assess the reversibility of cyclic tetrapeptide inhibition, 300 µL samples were prepared 
of 10 µM HDAC8His with no inhibitor, 100 µM trapoxin A, or 100 µM apicidin in size exclusion 
buffer supplemented with 0.25% DMSO. These were incubated at room temperature for 1 hour 
and then transferred into 10 kDa MWCO Slide-a-LyzerTM cassettes (Thermo Scientific) and 
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dialyzed against 3 L of size exclusion buffer at 4˚C. After 6 hours, 100 µL was extracted from each 
cassette and the remaining 200 µL was dialyzed against 2 L of fresh size exclusion buffer overnight. 
 After the initial 1 hour incubation, as well as the first and second round of dialysis, a standard 
discontinuous coupled fluorogenic assay was run to assess enzyme activity using the Fluor de Lys® 
HDAC8 tetrapeptide assay substrate Ac-Arg-His-Lys(Ac)-Lys-(Ac)-aminomethylcoumarin 
(AMC) (BML-KI178-0005; Enzo Life Sciences). Lysine deacetylation by HDAC8 was meas-
ured by cleavage of the amide bond with the AMC group by trypsin, resulting in red-shifted 
fluorescence. The signal was then fit to a standard curve to quantify product concentration. 
 Assays were performed in triplicate at room temperature. HDAC8His was diluted to 1 uM 
in size exclusion buffer and the assay substrate was diluted to 300 µM in activity assay buffer [25 
mM Tris (pH 8.2), 137 mM NaCl, 2.7 mM KCl, and 1 mM MgCl2]. Then, 25 µL of enzyme 
and 25 µL of substrate were mixed and incubated at room temperature in the dark for 30 min. 
The reaction was quenched by the addition of 50 µL of assay buffer containing trypsin and 200 
µM suberoylanilide hydroxamic acid (SAHA; Cayman Chemical), a pan-HDAC inhibitor. Fol-
lowing 30 min of development in the dark, fluorescence was measured using a Tecan Infinite 
M1000Pro plate reader (lex = 360 nm, lem = 460 nm). Specific activity assays of wild-type 
HDAC8His and HDAC8374 were performed in the same manner and processed using a standard 
curve generated by correlating known product concentrations with the signal following trypsin 
digestion. Data were averaged and plotted using GraphPad Prism. 
2.2.7 – Isothermal Titration Calorimetry 
  Experiments were performed with wild-type and Y306F HDAC8His, as well as wild-type 
HDAC8374, for both trapoxin A and apicidin while H142A and C153S HDC8His were studied 
with trapoxin A only. Heat curves were measured using a MicroCal iTC200 isothermal titration 
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calorimeter (Malvern). For trapoxin A, 200 µM inhibitor was titrated against 20 µM enzymes in 
size exclusion buffer containing 0.5% DMSO. Due to the limited solubility of apicidin in aqueous 
media, 100 µM inhibitor was titrated against 10 µM enzymes in size exclusion buffer with 5% 
DMSO. Forty 1-µL injections were made over 80 min except for the titration of apicidin against 
Y306F HDAC8His. This experiment used twenty 2-µL injections over 1 hour to increase the ob-
served heat per injection. Integration, curve fitting, and figure generation were performed using 
Origin (OriginLab, Northampton, MA). 
2.2.8 – Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry 
  MALDI mass spectrometry was used to verify the modification state of a sample of 50 µM 
HDAC8His incubated with 500 µM trapoxin A at 37˚C for 18 hours prior to its submission for 
LC-MS/MS analysis. After incubation, 2 µL were removed and mixed with 10 µL of saturated 
sinapic acid (Sigma-Aldrich) in 50:50 acetonitrile:0.1% aqueous trifluoroacetic acid and then a 2 
µL sample of the resulting solution was transferred to a 384-spot steel MALDI target plate 
(Bruker). Once the matrix had crystallized and the spots were dry, mass spectra were obtained on 
a Bruker Ultraflex III TOF/TOF mass spectrometer with 2000 shots per spot at 50% laser power. 
Data were processed in flexAnalysis (Bruker Daltonics) and mass spectra were plotted in 
GraphPad Prism. 
2.2.9 – Tryptic Peptide LC-MS/MS 
  Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to search for 
sites of modification of HDAC8 by trapoxin A, focusing on His and Cys residues since the closest 
potential nucleophiles to the epoxide in the HDAC8 complex were H142 and C153. Runs of LC-
MS/MS were carried out on HDAC8His alone in size exclusion buffer as a control as well as sam-
ples consisting of (1) 480 µM HDAC8His with 480 µM trapoxin A, (2) 50 µM HDAC8His with 
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200 µM TpxA, and (3) 50 µM HDAC8His with 500 µM TpxA. Samples 1 and 2 were incubated 
at room temperature for 1 hour while sample 3 was incubated at 37˚C for 18 hours. Peaks con-
sistent with mono- and di-labeled HDAC8His with TpxA were observed for sample 3 by MALDI 
prior to LC-MS/MS analysis. 
  LC-MS/MS was carried out at the Wistar Institute Proteomics and Metabolomics Facil-
ity. Samples were reduced with 15 mM TCEP for 30 min and then alkylated with 15 mM iodo-
acetamide for 45 min. The reaction was quenched by incubation with 35 mM L-cysteine for 15 
min prior to tryptic digestion. The samples were digested with trypsin overnight in the absence of 
denaturant. LC-MS/MS data were collected on a Q-HF mass spectrometer. MaxQuant 1.5.2.8 
was used to search mass spectra against the UniProt E. coli database plus the sequence of 
HDAC8His allowing for N-terminal acetylation, Met oxidation, Asn deamidation, C carbami-
domethylation, and a mass addition of 602.3 Da at His or Cys residues corresponding to modifi-
cation by trapoxin A. Modification by trapoxin A was observed at 6 sites in run 1, 10 sites in run 
2, and 15 sites in run 3 (4 of which were His residues in the hexahistidine tag). 
2.2.10 – Liquid Chromatography-Mass Spectrometry (LC-MS) 
  LC-MS was used to determine the observed mass of HDAC8 in the presence and absence 
of trapoxin A. Previously, it had been proposed that trapoxin A covalently modifies the enzyme in 
the folded state, but upon denaturation it is hydrolyzed from the enzyme.101 A sample of 200 µM 
trapoxin A was incubated in size exclusion buffer plus 0.5% DMSO for 1 hour with and without 
200 µM HDAC8374. A 50 µL aliquot of each sample was then diluted with 50 µL of acetonitrile, 
filtered via centrifugation, and submitted to LC-MS analysis. A 2 µL aliquot was then injected 
over a C18 reverse phase column with a gradient from 95:5 water:acetonitrile on a Waters Acquity 
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UPLC-MS. Mass spectra were processed using MassLynx software (Waters) and plotted using 
GraphPad Prism. 
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Table 2.1 | Structural statistics for the HDAC8374–trapoxin A complex 
HDAC8374–trapoxin A 
Unit Cell 
Space group P32 
a, b, c (Å) 50.98, 50.98, 116.52 
a, b, g (˚) 90.0, 90.0, 120.0 
Data Collection 
Wavelength (Å) 0.97949 
Resolution (Å) 44.15–1.24 
Total / unique no. of reflections 456,789 / 95,873 
Rmergea,b 0.046 (0.592) 
Rpima,c 0.035 (0.440) 
CC1/2a,d 0.999 (0.671) 
I/s(I)a 13.7 (2.2) 
Redundancya 4.8 (4.7) 
Completeness (%)a 99.1 (99.7) 
Refinement 
No. of reflections used in re-
finement / test set 95,808 / 9,680 
Rworka,e 0.121 (0.209) 
Rfreea,e 0.143 (0.253) 
No. of nonhydrogen atoms:  
protein 2,912 
ligand 108 
solvent 383 
Average B-factors (Å2)  
protein 17 
ligand 22 
solvent 30 
Root-mean-square deviation 
from ideal geometry  
bonds (Å) 0.009 
angles (˚) 1.0 
Ramachandran plot (%)f  
favored 98.1 
allowed 1.9 
PDB accession code 5VI6 
aValues in parentheses refer to data in the highest shell. bRmerge = ∑hkl∑i|Ii,hkl − ⟨I⟩hkl|/∑hkl∑i Ii,hkl, where ⟨I⟩hkl is the average 
intensity calculated for reflection hkl from replicate measurements. cRp.i.m.= (∑hkl(1/(N-1))1/2∑i|Ii,hkl − ⟨I⟩hkl|)/∑hkl∑i Ii,hkl, 
where ⟨I⟩hkl is the average intensity calculated for reflection hkl from replicate measurements and N is the number of 
reflections dPearson correlation coefficient between random half-datasets. eRwork = ∑||Fo| − |Fc||/∑|Fo| for reflections 
contained in the working set. |Fo| and |Fc| are the observed and calculated structure factor amplitudes, respectively. Rfree 
is calculated using the same expression for reflections contained in the test set held aside during refinement. fCalculated 
with PROCHECK.109  
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2.3 | Results & Discussion 
The structure of the HDAC8–trapoxin A complex at 1.24 Å resolution (Figure 2.2) 
reveals that the conformation of the tetrapeptide backbone of trapoxin A is identical to that 
observed in the crystal structure of the uncomplexed inhibitor99, with root-mean-square deviations 
(rmsd) of 0.21–0.24 Å for 16 main chain atoms of the cyclic peptide backbone; the L-Aoe side 
chains adopt different conformations (Figure 2.3). All peptide linkages of trapoxin A adopt the 
trans configuration except for the Phe-hPro linkage, which forms a cis-peptide. All three backbone 
NH groups donate hydrogen bonds to the side-chain carboxylate group of D101. The hydrogen 
bonds between D101 and the backbone NH groups of L-Aoe and the adjacent L-Phe residue are 
similar to those observed between D101 and linear tetrapeptide substrates bound to inactivated 
HDAC8 (Figure 2.4).73,110 Apart from interactions described below for the L-Aoe side chain, no 
other direct enzyme-inhibitor hydrogen bonds are observed. Although there are no intramolecular 
hydrogen bonds in trapoxin A, the side chains of its two L-Phe residues make a favorable 
quadrupole-quadrupole interaction with edge-to-face geometry.  
Conformational changes are required in the enzyme active site to accommodate the steric 
bulk of the rigid peptide macrocycle in comparison with substrate binding, primarily in the L2 
loop (residues G86-I108, of which D87-I94 are disordered). Relative to the structure of H143A 
HDAC8 complexed with a tetrapeptide substrate,73 the greatest change is observed for Y100, 
which undergoes a 116˚ change in side chain torsion angle c1 (Figure 2.4). Similar conformational 
flexibility of Y100 accommodates the binding of the macrocyclic depsipeptide inhibitor 
largazole.92 In the HDAC8–trapoxin A complex, the conformational change of Y100 is triggered 
by one of the inhibitor L-Phe residues, with which one of two observed conformers makes a 
favorable edge-to-face interaction. 
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Figure 2.2 | HDAC8–trapoxin A complex at 1.24 Å resolution 
(a) Stereoview of trapoxin A (orange) bound in the active site of HDAC8 (blue). The simulated 
annealing omit map for trapoxin A (green) is contoured at 3.0s. Metal coordination and hydrogen 
bonding interactions are presented as solid and dashed black lines, respectively. (b) Close-up ste-
reoview showing the zinc-bound gem-diolate.  
36 
 
 
 
Figure 2.3 | Free and enzyme-bound trapoxin A 
Conformation of trapoxin A as bound to HDAC8 (orange) superimposed on the three molecules 
in the asymmetric unit of the uncomplexed trapoxin A crystal structure (CSD ID: TALDEP; cyan, 
light blue, blue). The side chain conformation of L-Aoe in the uncomplexed inhibitor differs from 
that observed in the enzyme-bound inhibitor.   
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Figure 2.4 | Trapoxin A and peptide substrate binding 
Superposition of trapoxin A (orange) bound to HDAC8 (blue ribbon) and the coumarinyl peptide 
substrate RHK(Ac)K(Ac)-aminomethylcoumarin (green) bound to H143A HDAC8 (grey ribbon; 
PDB ID: 3EWF).73 Selected residues are labeled. Metal coordination interactions are shown as 
black lines, hydrogen-bonds with trapoxin A are shown as black dashes, and the D101-substrate 
hydrogen bonds are shown as gold dashed lines. A water-mediated hydrogen bond is observed 
between the L-Aoe carbonyl of trapoxin A and the imidazole side chain of H180, a metal-binding 
residue. Trapoxin A binding causes parts of the L2 loop to become disordered and Y100 to rotate 
outward. One major conformation of Y100 is observed, but residual electron density suggests the 
presence of another minor conformation making a favorable edge-to-face interaction with a Phe 
side chain of trapoxin A.  
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Surprisingly, the ketone carbonyl of the L-Aoe side chain undergoes nucleophilic attack 
by water upon binding to HDAC8, such that the inhibitory species is a gem-diolate (or perhaps 
a gem-diol) stabilized by Zn2+ coordination and three hydrogen bonds. Thus, trapoxin A mimics 
the binding of the tetrahedral intermediate and its flanking transition states in catalysis; the origins 
of high affinity are undoubtedly rooted in the fact that trapoxin A binds as an analogue of the 
postulated transition state. The Zn2+–O1 and Zn2+–O2 distances for the gem-diolate are 2.5 Å 
and 1.9 Å, respectively. The O1 hydroxyl group also forms hydrogen bonds with H142 and H143 
(O---O separations = 2.7 Å each), and the O2 oxyanion accepts a hydrogen bond from the phenol 
oxygen of Y306 (O---O separation = 2.6 Å). While it is unusual to see an unactivated ketone 
binding as a tetrahedral gem-diolate, which exists to less than 0.2% in aqueous solution (based on 
the hydration of the unactivated ketone carbonyl of acetone in aqueous solution),111 it is notable 
that the L-Aoe side chain of the cyclic tetrapeptide inhibitor HC toxin (Figure 2.1) similarly 
undergoes nucleophilic attack in the recently-determined structure of its complex with catalytic 
domain 2 of HDAC6.48 This behavior is also reminiscent of the binding of unactivated aldehyde 
and ketone substrate analogues to carboxypeptidase A, which similarly bind as tetrahedral gem-
diolate transition state analogues.112,113 
In the HDAC8–trapoxin A complex, the epoxide ring of the L-Aoe side chain is clearly 
intact and makes no hydrogen bond interactions with any enzyme residues or water molecules 
(Figure 2.2b). The closest side chains to the epoxide moiety are those of W141, H142, C153, and 
Y306 with interatomic separations of 3.3–3.7 Å. The epoxide moiety is believed to be required for 
essentially irreversible inhibitory activity against class I HDACs,99 based on the lack of irreversible 
inhibitory activity for the cyclic tetrapeptide inhibitor apicidin (Figure 2.1), which lacks an epoxide 
moiety. Thus, it is curious that the epoxide moiety of trapoxin A does not react with the enzyme. 
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However, the crystal structure reveals that although the epoxide moiety binds in the vicinity of 
catalytic general base H143 and highly conserved C153, neither of these potential nucleophiles is 
positioned or oriented for nucleophilic attack at the epoxide (Figure 2.2b). 
  We confirmed the irreversibility of trapoxin A inhibition by assaying HDAC8 activity 
following multiple rounds of dialysis of the enzyme-inhibitor complex. Regeneration of activity 
was not observed for HDAC8 preincubated with a 10-fold molar excess of trapoxin A, but was 
observed under the same conditions using apicidin (Figure 2.5). This result confirms that the 
epoxide moiety is required for essentially irreversible inhibition. However, this result does not 
prove that a covalent enzyme-inhibitor complex is formed.  
To study the covalent modification of HDAC8 by trapoxin A in solution, we employed 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) on HDAC8 preincubated for 
18 hours with 10 molar equivalents of trapoxin A and subsequently digested with trypsin. Prior to 
digestion, mass peaks corresponding to HDAC8 covalently modified with one or two trapoxin A 
molecules were observed for this sample by MALDI mass spectrometry (Figure 2.6). Following 
trypsin digestion, LC-MS/MS analysis, and sequence analysis for residue modifications, a mass 
shift corresponding to the molecular weight of trapoxin A was sporadically observed for various 
cysteine and histidine residues located on the surface of HDAC8 (Figure 2.7; Table 2.2). Only 
nonspecific labeling of the enzyme was observed in the presence of excess inhibitor, with no 
particular preference for covalent modification in the active site. Additionally, incubation of 
trapoxin A for 1 hour in the presence and absence of HDAC8 followed by LC-MS analysis 
indicated the presence of only intact trapoxin A (i.e., with an intact epoxide ring; Figure 2.8). 
These results strongly suggest that trapoxin A is simply an exceptionally tight-binding, 
noncovalent transition state analogue inhibitor of HDAC8. As noted by Schramm and  
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Figure 2.5 | HDAC8 inhibitor reversibility assays 
Recovered HDAC8 activity from samples incubated with DMSO, apicidin, and trapoxin A 
(TpxA) after no (gray), one (orange) or two (blue) rounds of dialysis against 104-fold excess fresh 
buffer.  
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Figure 2.6 | MALDI mass spectra for HDAC8 incubated with trapoxin A 
MALDI mass spectra of HDAC8His incubated with DMSO (black) or trapoxin A (TpxA, blue) at 
37˚C for 18 h prior to LC-MS/MS experiment.  
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Figure 2.7 | Trapoxin A-modified sites in HDAC8 by LC-MS/MS 
Of the 17 modified sites, 16 are shown here because one site of modification, the hexahistidine tag, 
is disordered and hence not observed in the crystal structure. Modification was observed in one 
(cyan), two (green), or three (red) replicates. Modification percentages are shown in Table 2.2. 
Only H51 and C244 were modified in all trials, with total modification fractions ranging from 1.5–
9.5%. The only sites with modification fractions exceeding 20% in a single trial were surface resi-
dues C352, H375, and residues in the hexahistidine tag at levels ranging 23-50%. Labeling of the 
tandem catalytic histidines H142 and H143, zinc ligand H180, and C153 was observed with mod-
ification fractions ranging 0.6-9.0% for any one of these residues.  
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Table 2.2 | Trapoxin A-modified sites in HDAC8 by LC-MS/MS 
 
Nobs refers to the total number of times that a residue was observed. Nmod refers to the number of 
times that the residue was detected with a mass addition consistent with trapoxin A modification 
 
 Run 1 Run 2 Run 3 
[HDAC8His] (uM) 480 50 50 
[trapoxin A] (uM) 480 200 500 
Incubation RT* for 1 hour RT* for 1 hour 37˚C for 18 hours 
Residue Nobs Nmod Nobs Nmod Nobs Nmod 
H42 ––––––––––– 207 5 170 6 
H51 21 2 207 2 170 11 
H71 ––––––––––– 223 2 228 1 
H78 77 1 ––––––––––– 228 1 
C102 11 2 ––––––––––– ––––––––––– 
H142 ––––––––––– 157 14 ––––––––––– 
H143 ––––––––––– 157 1 63 2 
C153 27 2 ––––––––––– ––––––––––– 
H180 ––––––––––– ––––––––––– 112 2 
H201 22 1 ––––––––––– 42 5 
C244 51 1 100 2 46 1 
C275 ––––––––––– 89 2 11 1 
C314 ––––––––––– 98 1 ––––––––––– 
H334 ––––––––––– 98 2 ––––––––––– 
C352 ––––––––––– 98 4 43 10 
H375 ––––––––––– 12 1 14 4 
HisTag ––––––––––– ––––––––––– 20 10 
*RT = room temperature  
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Figure 2.8 | Mass spectra of trapoxin A in the presence and absence of HDAC8 
Normalized mass spectra of trapoxin A (TpxA) incubated in the presence (blue) and absence (red) 
of HDAC8. Monoisotopic mass peaks corresponding to the mass of trapoxin A plus a proton, 
sodium ion, water, and potassium ions are labeled. Interestingly, an additional peak is observed in 
mass spectra of both samples that is consistent with monohydrated trapoxin A. This could reflect 
the enhanced reactivity of the a,b-epoxyketone carbonyl resulting in a higher percentage of the 
gem-diol in solution.  
45 
 
colleagues,114 transition state analogues with essentially irreversible binding behavior are feasible 
for enzymes that exhibit catalytic rate enhancements of 1010 or greater, which is likely the case for 
an amide hydrolase such as HDAC8 based on uncatalyzed amide bond hydrolysis half-lives 
measured in centuries by Radzicka and Wolfenden.115 
Isothermal titration calorimetry (ITC) measurements yield HDAC8 dissociation 
constants Kd = 3 ± 1 nM for trapoxin A and Kd = 250 ± 70 nM for apicidin (Figure 2.9), indicating 
83-fold enhanced binding affinity for trapoxin A relative to apicidin. Given the structural 
similarity between the two cyclic tetrapeptides, and the fact that the macrocycle makes very few 
intermolecular interactions in the HDAC8–trapoxin A complex, it is clear that the epoxide moiety 
of trapoxin A is indeed responsible for tight binding to HDAC8.  
ITC measurements of HDAC8 active site variants indicate that H142 is critical for 
trapoxin A binding just as it is important for catalysis, since the H142A mutation results in 
significantly weaker affinity with Kd = 17 ± 5 μM – H142A HDAC8 exhibits a 233-fold reduced 
kcat/KM value relative to wild-type HDAC8.77 This residue functions in catalysis with a positively 
charged imidazolium group that serves as an electrostatic catalyst.77 Electron density is observed 
for the Nε-H proton of H142 in the 1.24 Å electron density map (Figure 2.10), so the H142 
imidazolium group must similarly stabilize the zinc-bound gem-diolate.  
Although the L-Aoe side chains of trapoxin A and HC toxin bind to HDAC8 and 
HDAC6, respectively, as the gem-diolate, there are notable differences between the structures of 
each enzyme-inhibitor complex that may explain the tighter binding of these inhibitors to class I 
HDACs.102 In the class IIb HDAC6-HC toxin complex (Ki = 350 nM),48 the C–O bond of the 
epoxide adopts an energetically unfavorable eclipsed conformation with respect to the C–O bond 
of the hydroxyl group of the zinc-bound gem-diolate (Figure 2.11a); in the class I HDAC8– 
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Figure 2.9 | ITC thermograms for HDAC inhibitor binding 
Isothermal titration calorimetry (ITC) thermograms and corresponding binding isotherms derived 
from integrating thermograms using the one-site model. Measurements were made for: 200 µM 
trapoxin A versus 20 µM wild-type, H142A, C153S, and Y306F HDAC8; and 100 µM apicidin 
versus 10 µM wild-type and Y306F HDAC8. The HDAC8 construct bearing the hexahistidine 
tag, HDAC8His, was used for these measurements. The wild-type tagless construct, HDAC8374, 
was also studied with trapoxin A and apicidin using identical conditions. Thermodynamic constants 
for each run are calculated from curve fitting and inlaid in each plot. 
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Figure 2.10 | Omit map for hydrogen atoms in HDAC8-trapoxin A complex 
Simulated annealing omit map contoured at 2.5σ showing hydrogen atoms in the HDAC8-
trapoxin A complex. The zinc ion is indicated by a gray sphere. A large electron density peak cor-
responds to the Ne-H atom of H142, indicating that this residue is in the positively charged imid-
azolium state. 
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Figure 2.11 | Zinc coordination interactions in HDAC8–inhibitor complexes 
(a) HDAC8-trapoxin A complex, PDB 5VI6. (b) HDAC8-trichostatin A complex, PDB 1T64. 
(c) HDAC8-largazole complex, PDB 3RQD.  
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trapoxin A complex (Kd = 3 nM), the C–O bond of the epoxide adopts an energetically favorable 
staggered conformation (Figure 2.11b). The energetically unfavorable eclipsed conformation in 
the HDAC6-HC toxin complex appears to be caused by the bulky P571 residue in the L3 loop, 
conserved in all class II HDACs – if the epoxide adopted an energetically favorable staggered 
conformation in the HDAC6 active site, the epoxide methylene group would clash with P571. In 
class I HDACs, P571 is not conserved and the active site is more open. Thus, a more favorable 
binding conformation is accessible to the epoxyketone moiety only in the active site of a class I 
HDAC. 
Although the a,b-epoxyketone epoxide moiety of trapoxin A remains intact in the crystal 
structure of its complex with HDAC8, it is notable that this novel functionality is chemically 
reactive in the binding of inhibitors to other enzymes. For example, the proteasome inhibitor 
carfilzomib contains an a,b-epoxyketone that forms a covalent adduct to block proteasome 
function 116. The crystal structure of a similar natural product, epoxomicin, complexed with the 
yeast 20S proteasome indicates a multistep cyclization sequence leading to the formation of a 
morpholino ring between the former a,b-epoxyketone of the inhibitor and the reactive N-terminal 
threonine residue of the proteasome subunit 117. A two-step mechanism for inhibitor binding is 
initiated by nucleophilic attack of the threonine hydroxyl group at the epoxyketone carbonyl 
followed by a 6 Exo-Tet ring closure reaction between the a-amino group of threonine and the 
epoxide to generate the morpholino product.118 
The chemistry of inhibitor binding in this system indicates that the carbonyl group appears 
to be more reactive than the epoxide of the a,b-epoxyketone moiety. This is consistent with 
reactivity trends observed in organic synthesis for various a,b-epoxycarbonyl derivatives, where 
the carbonyl group preferentially undergoes nucleophilic addition while leaving the epoxide moiety 
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intact.119–121 With respect to trapoxin A, it is notable that an additional peak is observed in mass 
spectra consistent with gem-diol formation even in the absence of enzyme (Figure 2.8).  
Finally, it is interesting to compare the structures of zinc coordination polyhedra in 
different HDAC8-inhibitor complexes (Figure 2.12). Only one oxygen of the gem-diolate of 
trapoxin A is sufficiently close for inner-sphere coordination, so the overall zinc coordination 
geometry is best described as 4-coordinate distorted tetrahedral. In this regard, the zinc 
coordination geometry approaches that observed in the HDAC8–largazole complex, which 
exhibits nearly perfect tetrahedral coordination through the binding of the largazole thiolate 
group.92 In contrast with these examples, the hydroxamate group of trichostatin A coordinates to 
zinc in bidentate fashion, so that the overall coordination geometry is 5-coordinate square 
pyramidal.51 
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Figure 2.12 | Epoxyketone binding modes in different classes of HDACs 
(a) Head-on view of the HC toxin gem-diol (yellow) bound to HDAC6 (red) alongside a surface 
contour of the HDAC6 active site cavity showing the steric interactions forcing the eclipsed 
orientation of the epoxyketone relative to the gem-diol. (b) Head-on view of the trapoxin A gem-
diol (orange) bound to HDAC8 (blue) alongside a surface contour of the HDAC8 active site 
cavity showing the presence of an active site groove that accommodates the staggered orientation 
of the epoxyketone relative to the gem-diol. 
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2.4 | Conclusion 
In conclusion, the work presented here demonstrates that trapoxin A is an essentially irre-
versible noncovalent inhibitor of HDAC8: the a,b-epoxyketone side chain of the inhibitor un-
dergoes nucleophilic attack by zinc-bound water to bind as a tetrahedral gem-diolate transition 
state analogue. Along with a favorable staggered conformation of the intact epoxide moiety relative 
to the zinc-bound gem-diolate, these structural features contribute to an exceptionally tight en-
zyme-inhibitor complex effectively locked into the enzyme active site. This provides a starting 
point for the design of inhibitors exploiting this binding environment for the development of tar-
geted scientific and clinical tools. 
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Chapter 3 | Hydroxamate Denticity in HDAC6 Inhibition 
Work presented here is reprinted from Porter, N.J.; Mahendran, A.; Breslow, R.; Christianson, 
D.W. Proc. Natl. Acad. Sci. USA 2017, 114, 13459-13464. All crystallography was performed by 
N.J.P. The HDAC inhibitor HPB was prepared by A.M. 
 
3.1 | Introduction 
  Among the HDAC isozymes, HDAC6 is distinct by virtue of its localization in the cyto-
plasm, as signaled by a serine/glutamate-rich repeat,122 as well as its biological function.123,124 Ad-
ditionally, HDAC6 is the only isozyme that contains two catalytic domains, CD1 and CD2, the 
structures of which have recently been solved.48,49 One of these domains, CD2, catalyzes the 
deacetylation of K40 of a-tubulin in the lumen of the microtubule.67,125 Consequently, inhibition 
of HDAC6 results in microtubule hyperacetylation and suppression of microtubule dynamics, 
leading to cell cycle arrest and apoptosis.125,126 HDAC6 is thus a critical target for the design of 
isozyme-selective inhibitors for use in cancer chemotherapy.127,128 
  Significant advances have been made in the development of HDAC6-selective inhibitors, 
examples being Tubastatin,129 N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-ox-
oethyl)benzamide (HPOB),130 N-hydroxy-4-[(N(2-hydroxyethyl)-2-phenylacetamido)methyl)-
benzamide)] (HPB),131 ACY-1215 (Ricolinostat),132 and ACY-1083133 (Figure 3.1). These inhib-
itors exhibit HDAC6 selectivities ranging from 12- to greater than 1000-fold relative to class I 
enzymes such as HDAC1. Each of these inhibitors targets Zn2+ coordination with a hydroxamate 
group; HDAC6 selectivity is thought to be dictated by bulky capping or linker groups compared 
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with pan-HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA) or trichostatin A 
(TSA) (Figure 3.1). 
  To determine molecular features responsible for HDAC6-selective inhibition, we deter-
mined crystal structures of inhibitor complexes with the CD2 domain of Danio rerio (zebrafish) 
HDAC6, referred to simply as "HDAC6" for the remainder of this chapter. Recent structural and 
functional studies from the Christianson lab have demonstrated that zebrafish HDAC6 is a vali-
dated and more readily-crystallized surrogate of human HDAC6, the actual drug target.48 Here, 
crystal structures of HDAC6 complexed with the HDAC6-selective inhibitors HPB and ACY-
1083 reveal a common monodentate hydroxamate-Zn2+ binding mode similar to that recently ob-
served in the crystal structure of the HDAC6–HPOB complex.48 Thus, this unusual binding mode 
is a signature of selectivity for the binding of these bulky phenylhydroxamate inhibitors to 
HDAC6. In contrast, the crystal structure of the HDAC6 complex with Ricolinostat reveals a 
canonical bidentate hydroxamate-Zn2+ chelate complex, so the isozyme selectivity of this inhibitor 
is rooted solely in the interactions of its bulky capping group. Intriguingly, the 1.05 Å-resolution 
structure of the HDAC6 complex with the R-stereoisomer of TSA reveals two Zn2+ binding 
modes for this pan-HDAC inhibitor: the major binding mode corresponds to the canonical bi-
dentate hydroxamate-Zn2+ complex observed in the previously determined 1.59 Å-resolution 
structure,48 and the minor binding mode corresponds to the unusual monodentate Zn2+ complex 
observed exclusively for HPB, HPOB, and ACY-1083. 
55 
 
 
Figure 3.1 | Selectivity of HDAC inhibitors for HDAC6 over HDAC1 
Selectivity of hydroxamate-based inhibitors for inhibition of HDAC6 versus HDAC1 based on 
IC50 assays. Values were obtained from: aRef. 131; bRef. 49; cRef. 132; dRef. 130; eRef. 133; fRef. 
136.  
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3.2 | Materials & Methods 
3.2.1 – Reagents 
In general, chemicals used in buffers and crystallization were acquired from Fisher, Milli-
pore Sigma, or Hampton Research and used without further purification. The inhibitor HPB was 
synthesized according to published procedures by the Breslow lab.131 Ricolinostat and ACY-1083 
were the generous gift of Acetylon (now Bristol-Myers-Squibb). 
3.2.2 – Protein Preparation 
  HDAC6 catalytic domain 2 from Danio rerio (henceforth simply "HDAC6") was recom-
binantly expressed using the MBP-TEV-z6CD2-pET28a(+) vector and purified as previously de-
scribed with minor modifications.48 Briefly, HDAC6 was expressed by the E. coli BL21 (DE3) 
strain (Stratagene) in 2x YT medium under the selection of 50 mg/L kanamycin. Expression was 
induced by 100 µM isopropyl b-L-1-thiogalactopyranoside (IPTG; Gold Biotechnology) along 
with the addition of 200 µM ZnCl2 at 16 ˚C. Cells were collected by centrifugation and stored at 
-80 ˚C prior to purification. 
  Pellets were thawed and resuspended in purification buffer [50 mM 4-(2-hydroxyethyl)-
1-piperazine-ethanesulfonic acid (HEPES; pH 7.5), 300 mM KCl, 10% glycerol (v/v), 1 mM 
tris(2-carboxyethyl)phosphine (TCEP)] and lysed by sonication. Lysate was clarified by centrifu-
gation at 33,000g for 1 hour at 4 ˚C. The supernatant was purified using an amylose column (New 
England BioLabs) and protein was eluted using 10 mM maltose. Protein was digested using re-
combinant His-TEV protease overnight at 4 ˚C while dialyzing in purification buffer + 20 mM 
imidazole. The digest was applied to an equilibrated Ni-NTA resin (Qiagen) to remove His-MBP 
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and His-TEV, which were subsequently eluted with a 0–400 mM imidazole gradient in purifica-
tion buffer. The HDAC6-containing fractions were concentrated to <10 mL over a 10kDa 
MWCO filter unit (Millipore) and applied to a HiLoad Superdex 200pg column in size exclusion 
buffer [50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM TCEP]. Fractions 
containing pure HDAC6 were identified using SDS-PAGE, pooled, and concentrated to 14–20 
mg/mL. Protein was flash cooled in liquid nitrogen and stored at -80 ˚C prior to usage. 
3.2.3 – Crystallization 
All HDAC6-inhibitor complexes were crystallized in sitting drops by the vapor diffusion 
method at 4 ˚C.  
  For cocrystallization of the HDAC6–HPB complex, a 350 nL drop of protein solution [10 
mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM TCEP, 5 
mM HPB, and 5% dimethyl sulfoxide (DMSO) (v/v)] was added to a 350 nL drop of precipitant 
solution [200 mM ammonium chloride and 20% (w/v) PEG 3,350] and equilibrated against an 
80 µL reservoir of precipitant solution. Hexagonal plate crystals appeared within 2 days. 
  For initial cocrystallization of the HDAC6–ACY-1083 complex, a 2 µL drop of protein 
solution [10 mg/mL HDAC6, 100 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 
mM TCEP, 5 mM ACY-1083, and 5% DMSO] was added to a 2 µL drop of precipitant solution 
[50 mM magnesium acetate, 100 mM sodium cacodylate (pH 6.5), and 25% (w/v) PEG 8,000] 
and equilibrated against a 500 µL reservoir of precipitant solution. A few rhombus-shaped crystals 
appeared after 1 week. These were crushed and used as a seed stock for streak-seeding cocrystal-
lization experiment using the same conditions except a lower protein concentration was used (5 
mg/mL HDAC6). This approach yielded many pyramid-shaped crystals within 1 day. 
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  For cocrystallization of the HDAC6–Ricolinostat complex, a 350 µL drop of protein so-
lution [10 mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM 
TCEP, saturating Ricolinostat (ca. 1 mM), and 5% DMSO (v/v)] was added to a 350 µL drop of 
precipitant solution [100 mM sodium citrate (pH 5.5) and 16% (w/v) PEG 8,000] and equili-
brated against an 80 µL reservoir of precipitant solution. Crystal plates appeared within 3 days. 
  For cocrystallization of HDAC6 with the R-stereoisomer of TSA, a 350 µL drop of pro-
tein solution [10 mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 
1 mM TCEP, 2 mM TSA, 5% DMSO] was added to 350 µL of precipitant solution [200 mM 
MgCl2, 100 mM Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (BisTris; pH 6.5), and 
25% (w/v) PEG 3,350] and equilibrated against an 80 µL reservoir of precipitant solution. Thick 
crystal plates appeared within 2 days. 
  All crystals were soaked in a cryoprotectant solution containing mother liquor supple-
mented with 20% glycerol (HDAC6–TSA) or 15% (HDAC6–ACY-1083), 20% (HDAC6–
HPB), or 25% (HDAC6–Ricolinostat) ethylene glycol prior to flash-cooling in liquid nitrogen. 
For the structural determination of HDAC6–R-TSA complexes at varied pH values, crystals were 
cryoprotected in precipitant solutions buffered with BisTris at pH values of 5.5, 6.0, 6.5, 7.0, and 
7.5, as well as 20% ethylene glycol. 
3.2.4 – Data Collection and Structure Determination 
X-ray diffraction data were collected from crystals on beamline 9-2 at the Stanford Syn-
chrotron Radiation Laboratory (SSRL), Stanford University (HDAC6–ACY-1083 and 
HDAC6–HPB complexes), beamline 4.2.2 at the Advanced Light Source (ALS), University of 
California-Berkeley (HDAC6–Ricolinostat complex), and on beamline 24-ID-C at the Advanced 
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Photon Source (APS), Argonne National Laboratory (HDAC6–TSA complex). Data were in-
dexed and integrated using either XDS134 (HDAC6–TSA, HDAC6–ACY-1083, and HDAC6–
Ricolinostat complexes) or iMosflm103 (HDAC6–HPB complex) and scaled using Aimless in the 
CCP4 program suite.104 Data collection statistics for these four structures are recorded in Table 
3.1. Statistics for the HDAC6-TSA complexes at varied pH values are presented in Table 3.2. 
  All crystal structures were solved by molecular replacement using the atomic coordinates 
of unliganded HDAC6 (PDB 5EEM)48 as a search model for rotation and translation function 
calculations using the program Phaser.105 Atomic models were constructed using the graphics pro-
gram Coot106 and crystallographic structure refinement was performed using PHENIX.107 Inhib-
itor molecules were added in the later stages of refinement. Occasionally, maps displayed spurious 
electron density peaks that could not be satisfactorily modeled by ordered solvent, in which case 
these were left interpreted. The overall quality of each model was assessed using MolProbity108 
and PROCHECK.109 Final refinement statistics are recorded in Table 3.1 and Table 3.2. 
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Table 3.1 | Structural statistics for HDAC6-inhibitor complexes 
Inhibitor TSA HPB Ricolinostat ACY-1083 
Unit Cell 
Space group P21 P22121 P212121 C2221 
a, b, c (Å) 48.4, 69.6, 50.2 51.7, 84.0, 94.6 87.2, 88.0, 119.0 97.8, 173.4, 149.1 
a, b, g (˚) 90.0, 110.42, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Data Collection 
Wavelength (Å) 0.97920 0.97946 1.00003 0.97946 
Resolution (Å) 47.04 – 1.05 62.79 – 1.82 49.3 – 1.70 48.91 – 1.75 
Total / unique no. of 
reflections 455704 / 138710 207193 / 37115 696967 / 101104 864102 / 127773 
Rmergea,b 0.067 (0.689) 0.103 (0.343) 0.139 (0.789) 0.189 (0.930) 
Rpima,c 0.043 (0.460) 0.047 (0.155) 0.057 (0.333) 0.078 (0.391) 
CC1/2a,d 0.998 (0.591) 0.995 (0.90) 0.996 (0.842) 0.989 (0.746) 
I/s(I)a 11.1 (1.9) 11.7 (4.7) 14.1 (2.7) 8.0 (2.2) 
Redundancya 3.3 (3.1) 5.6 (5.7) 6.9 (6.5) 6.8 (6.6) 
Completeness (%)a 95.6 (89.8) 99.1 (99.3) 99.9 (100.) 100.0 (99.9) 
Refinement 
No. of reflections 
used in refinement / 
test set 
138678 / 6928 37057 / 1812 100931 / 5089 127726 / 6481 
Rworka,e 0.113 (0.226) 0.149 (0.179) 0.184 (0.206) 0.163 (0.255) 
Rfreea,e 0.132 (0.237) 0.173 (0.233) 0.209 (0.240) 0.189 (0.275) 
No. of nonhydrogen 
atoms:     
protein 2960 2839 5682 8581 
ligand 109 127 186 247 
solvent 368 416 552 794 
Average B-factors 
(Å2)     
protein 9 11 14 16 
ligand 22 28 21 26 
solvent 25 23 23 25 
Root-mean-square 
deviation from ideal 
geometry 
    
bonds (Å) 0.009 0.012 0.019 0.011 
angles (˚) 1.16 0.89 1.24 1.11 
Ramachandran plot 
(%)f     
favored 97.45 97.16 96.47 97.29 
allowed 2.55 2.84 3.53 2.53 
disallowed 0.00 0.00 0.00 0.19 
PDB accession code 5WGI 5WGK 5WGL 5WGM 
aValues in parentheses refer to data in the highest shell. bRmerge = ∑hkl∑i|Ii,hkl − ⟨I⟩hkl|/∑hkl∑i Ii,hkl, where ⟨I⟩hkl is the average 
intensity calculated for reflection hkl from replicate measurements. cRp.i.m.= (∑hkl(1/(N-1))1/2∑i|Ii,hkl − ⟨I⟩hkl|)/∑hkl∑i Ii,hkl, 
where ⟨I⟩hkl is the average intensity calculated for reflection hkl from replicate measurements and N is the number of 
reflections dPearson correlation coefficient between random half-datasets. eRwork = ∑||Fo| − |Fc||/∑|Fo| for reflections 
contained in the working set. |Fo| and |Fc| are the observed and calculated structure factor amplitudes, respectively. Rfree 
is calculated using the same expression for reflections contained in the test set held aside during refinement. fCalculated 
with PROCHECK.109  
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Table 3.2 | Structural statistics for HDAC6-R-TSA complexes at variant pH values 
pH 5.5 6.0 6.5 7.0 7.5 
Unit Cell 
Space group P21 P21 P21 P21 P21 
a, b, c (Å) 48.3, 70.0, 50.5 48.4, 69.5, 50.6 48.3, 69.8, 50.5 48.3, 69.7, 50.6 48.4, 69.6, 50.6 
a, b, g (˚) 90.0, 110.29, 90.0 90.0, 110.4, 90.0 90.0, 110.4, 90.0 90.0, 110.4, 90.0 90.0, 110.4, 90.0 
Data Collection 
Wavelength (Å) 0.97918 0.97918 0.97918 0.97918 0.97918 
Resolution (Å) 47.41–1.40 47.44–1.40 45.28–1.40 47.43–1.40 47.42–1.40 
Total / unique no. 
of reflections 210,637 / 60,589 208,621 / 60,860 193,899 / 59,845 208,973 / 60,978 205,559 / 59,436 
Rmergea,b 0.120 (0.617) 0.056 (0.185) 0.158 (0.248) 0.044 (0.130) 0.072 (0.330) 
Rpima,c 0.077 (0.430) 0.036 (0.122) 0.103 (0.174) 0.028 (0.085) 0.045 (0.220) 
CC1/2a,d 0.990 (0.688) 0.997 (0.951) 0.957 (0.881) 0.998 (0.977) 0.996 (0.850) 
I/s(I)a 9.9 (2.8) 14.8 (6.8) 11.4 (7.0) 18.8 (9.1) 9.2 (4.2) 
Redundancya 3.3 (3.1) 3.4 (3.3) 3.2 (2.9) 3.4 (3.3) 3.5 (3.3) 
Completeness 
(%)a 97.6 (85.6) 98.4 (98.4) 96.9 (93.0) 98.5 (97.5) 96.0 (93.7) 
Refinement 
No. of reflections 
used in refine-
ment / test set 
60,553 / 2,936 60,833 / 2,947 59,801 / 5,676 60,956 / 2,955 59,422 / 2,878 
Rworka,e 0.139 (0.311) 0.103 (0.094) 0.137 (0.181) 0.105 (0.092) 0.113 (0.139) 
Rfreea,e 0.179 (0.369) 0.138 (0.161) 0.170 (0.245) 0.136 (0.153) 0.146 (0.191) 
No. of nonhydro-
gen atoms:      
protein 2989 2989 2989 2989 2989 
ligand 47 47 47 47 47 
solvent 446 446 446 446 446 
Average B-factors 
(Å2)      
protein 10 8 6 9 6 
ligand 13 11 8 11 8 
solvent 27 25 21 26 22 
Root-mean-
square deviation 
from ideal geom-
etry 
     
bonds (Å) 0.009 0.011 0.006 0.008 0.008 
angles (˚) 1.04 1.13 0.92 1.02 0.99 
Ramachandran 
plot (%)f      
favored 97.5 97.5 97.2 97.5 97.2 
allowed 2.5 2.5 2.8 2.5 2.8 
aValues in parentheses refer to data in the highest shell. bRmerge = ∑hkl∑i|Ii,hkl − ⟨I⟩hkl|/∑hkl∑i Ii,hkl, where ⟨I⟩hkl is the average 
intensity calculated for reflection hkl from replicate measurements. cRp.i.m.= (∑hkl(1/(N-1))1/2∑i|Ii,hkl − ⟨I⟩hkl|)/∑hkl∑i Ii,hkl, 
where ⟨I⟩hkl is the average intensity calculated for reflection hkl from replicate measurements and N is the number of 
reflections dPearson correlation coefficient between random half-datasets. eRwork = ∑||Fo| − |Fc||/∑|Fo| for reflections 
contained in the working set. |Fo| and |Fc| are the observed and calculated structure factor amplitudes, respectively. Rfree 
is calculated using the same expression for reflections contained in the test set held aside during refinement. fCalculated 
with PROCHECK.109  
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3.3 | Results 
3.3.1 – HDAC6–HPB Complex 
The 1.82 Å-resolution structure of the HDAC6–HPB complex does not reveal any signif-
icant conformational changes relative to unliganded HDAC6 (PDB 5EEM), and the root-mean-
square deviation (rmsd) between unliganded and inhibitor-bound structures is 0.14 Å for 284 Ca 
atoms. The hydroxamate group of HPB coordinates to the active site zinc ion only through its N–
O– group (Zn2+---O distance = 1.9 Å), which binds at the coordination site that would be occupied 
by the substrate carbonyl in catalysis (Figure 3.2a). The catalytic zinc-bound water molecule re-
mains in place and donates a hydrogen bond to the hydroxamate C=O group (O---O distance = 
2.6 Å). This water molecule also forms hydrogen bonds with H573 and H574. Additionally, the 
Y745 hydroxyl group interacts with the hydroxamate NH (O---N distance = 2.6 Å) and O– (O--
-O distance = 2.7 Å) groups.  
The phenyl linker group of HPB is sandwiched between F583 and F643 (Figure 3.2b). 
The peptoid capping group is observed in both the trans and cis conformations with respective 
occupancies of 0.66 and 0.34, corresponding to DG = 0.4 kcal/mol. This is within the range of 
0.3–0.6 kcal/mol measured for peptoid trans-cis isomerization,135 so the enzyme does not exhibit 
a clear preference for one conformation or the other. The phenyl group of the cis conformer makes 
a van der Waals contact with L1 loop residue P464; the energetically preferred trans conformation 
of the peptoid moiety allows the phenyl capping group to make a quadrupole-charge interaction 
with the side chain of R601 in an adjacent monomer. The hydroxyl moiety of the capping group 
forms a water-mediated hydrogen bond with S531 (Figure 3.2a). The side chain of S531 accepts  
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Figure 3.2 | HDAC6–HPB complex at 1.82 Å resolution 
(a) Simulated annealing omit map (green, contoured at 2.0σ) for cis (yellow) and trans (orange) 
conformations of HPB bound to HDAC6. Omit density is also shown for the water molecule (red 
sphere) bound to the Zn2+ ion (grey sphere). Metal coordination and hydrogen bond interactions 
are indicated by solid and dashed black lines, respectively. (b) Molecular surface of the HDAC6 
active site showing the aromatic ring of the phenylhydroxamate nestled between F583 and F643.  
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a hydrogen bond from the backbone NH group of the acetyl-L-lysine substrate, an interaction 
that is unique to the HDAC6 active site 48. 
3.3.2 – HDAC6–ACY-1083 Complex 
The 1.75 Å-resolution structure of the HDAC6–ACY-1083 complex does not reveal any 
major structural rearrangements caused by inhibitor binding, and the rmsd is 0.16 Å for 300 Ca 
atoms between the inhibitor-bound and unliganded enzymes. The hydroxamate moiety adopts 
monodentate Zn2+ coordination geometry identical to that observed in the HPB complex: the 
hydroxamate N–O– group coordinates to Zn2+ (Zn2+---O distance = 1.9 Å) and interacts with 
Y745 (O---O distance = 2.5 Å) (Figure 3.3a). The hydroxamate C=O group accepts a hydrogen 
bond from the Zn2+-bound water molecule (O---O distance = 2.7 Å); this water molecule also 
hydrogen bonds with H573 and H574. The hydroxamate NH group interacts with the side chain 
of Y745 (O---N distance = 2.7 Å).   
The aromatic ring of the aminopyrimidine linker is sandwiched between F583 and F643 
in a similar manner to that observed for the phenyl linker of HPB (Figure 3.3b). The hydroxyl 
side chain of S531 on the L2 loop accepts a hydrogen bond from the secondary amino group of 
the inhibitor (O---N distance = 3.1 Å) (Figure 3.3a). The difluorocyclohexyl capping group adopts 
a chair conformation, and the equatorial fluorine atom packs against the edge of the F643 side 
chain (F---C distance = 3.6 Å). The phenyl capping group of the inhibitor makes van der Waals 
interactions with the side chains of P464 and F583. 
3.3.3 – HDAC6–Ricolinostat 
The 1.70 Å-resolution structure of the HDAC6–Ricolinostat (ACY-1215) complex re-
veals that no major conformational changes are triggered by inhibitor binding, and the rmsd is  
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Figure 3.3 | HDAC6–ACY-1083 complex at 1.75 Å resolution 
(a) Simulated annealing omit map (green, contoured at 2.5σ) for ACY-1083 (orange) and the water 
molecule (red sphere) bound to the Zn2+ ion (large grey sphere) in the active site of HDAC6. Metal 
coordination and hydrogen bond interactions are indicated by solid and dashed black lines, respec-
tively. (b) Molecular surface of the HDAC6 active site showing the heteroaromatic ring of the 
inhibitor nestled between F583 and F643. The phenyl group of the capping group lies adjacent to 
F583 and also P464 (not shown in this view).  
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0.65 Å for 336 Ca atoms between the inhibitor-bound and unliganded enzymes. The hydrox-
amate moiety of Ricolinostat coordinates to Zn2+ in bidentate fashion (Figure 3.4), forming a 
canonical 5-membered chelate complex with Zn2+---O distances of 2.0 Å and 2.4 Å for the N–
O– and C=O groups, respectively. The side chain of Y745 donates a hydrogen bond to the hy-
droxamate C=O group (O---O distance = 2.7 Å), H573 donates a hydrogen bond to the hydrox-
amate N–O– group (N---O distance = 2.7 Å) and H574 accepts a hydrogen bond from the hy-
droxamate NH group (N---N distance = 2.9 Å). Hydrogen bond interactions with the tandem 
histidine residues suggest that H573 is in the positively charged imidazolium state and H574 is in 
the neutral imidazole state. These protonation states are consistent with the assignment of the 
second histidine in this tandem pair as a single general base-general acid in catalysis, as recently 
demonstrated for HDAC8.76,77 
Two monomers reside in the asymmetric unit of this crystalline enzyme-inhibitor complex. 
In one monomer, the inhibitor capping group adopts two mutually exclusive conformations (Fig-
ure 3.4). In one conformation, the amide carbonyl of the inhibitor capping group forms a water-
mediated hydrogen bond with S531 on the L1 loop. The aminopyrimidinyl ring nitrogen also 
forms a water-mediated hydrogen bond with D460. In the second conformation, a water-medi-
ated hydrogen bond is formed between the amide carbonyl of the inhibitor capping group and 
H614 (one of the Zn2+ ligands). The aminopyrimidinyl ring nitrogen also forms a water-mediated 
hydrogen bond with the carbonyl of P711. 
3.3.4 – HDAC6–TSA Complex 
The 1.05 Å-resolution structure of HDAC6 complexed with the R-stereoisomer of TSA 
complex reveals significantly more detail in comparison with the previously reported 1.59 Å-res-
olution structure of this complex (PDB 5EEK).48 Although the polypeptide backbones of  
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Figure 3.4 | HDAC6–Ricolinostat complex at 1.70 Å resolution 
Simulated annealing omit map (green, contoured at 2.5σ) for Ricolinostat bound to HDAC6 
(monomer A). Two conformations for the capping group are shown with different shades of purple, 
the darker of which indicates the sole conformation observed in monomer B. The Zn2+ ion is shown 
as a large grey sphere and water molecules are shown as smaller red spheres. Metal coordination 
and hydrogen bond interactions are indicated by solid and dashed black lines, respectively.   
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HDAC6 in the ultrahigh and high resolution structures are essentially identical (rmsd = 0.064 Å 
for 315 Ca atoms), the ultrahigh resolution structure reveals major and minor conformers for the 
hydroxamate group of TSA (Figure 3.5a). The minor conformation is not observable in crystal 
structures determined at lower resolution.48,49 
The major conformer of TSA (70% occupancy) corresponds to that described in the 1.59 
Å resolution structure, in which the canonical bidentate hydroxamate-Zn2+ coordination mode is 
observed with O---Zn2+ distances of 2.2 Å and 2.0 Å for the hydroxamate C=O and N–O– groups, 
respectively. Additionally, Y745 donates a hydrogen bond to the hydroxamate C=O, while H573 
and H574 form hydrogen bonds with the N–O– group (Figure 3.5b). 
The minor conformer of TSA (30% occupancy; Figure 3.5c) corresponds to the mono-
dentate hydroxamate-Zn2+ coordination mode observed for sterically bulky HDAC6-selective in-
hibitors such as HPOB, HPB, and ACY-1083. The hydroxamate group of TSA coordinates to 
Zn2+ only through its N–O– group (Zn2+---O distance = 1.8 Å), which binds at the coordination 
site that would be occupied by the substrate carbonyl in catalysis. Weak electron density is ob-
served for the Zn2+-bound water molecule, which donates a hydrogen bond to the hydroxamate 
C=O group (O---O distance = 2.8 Å). Additionally, the hydroxyl group of Y745 is within hydro-
gen bonding distance to the hydroxamate NH and N–O– groups with O---N and O---O distances 
of 2.7 Å and 2.8 Å, respectively.  
  Other than differences in the conformation and orientation of the hydroxamate group, no 
other structural features distinguish the major and minor conformers of TSA. The dimethylhep-
tadiene linker and p-dimethylaminophenyl capping group bind in identical fashion in high- and 
low-occupancy conformations. Based on the 70:30 ratio observed for bidentate:monodentate Zn2+  
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Figure 3.5 | HDAC6–R-TSA complex at 1.05 Å resolution 
(a) Simulated annealing omit map (green, contoured at 2.5σ) of the R-stereoisomer of TSA bound 
to HDAC6, showing the binding of major (purple) and minor (orange) inhibitor conformations. 
(b) Omit map of the major TSA conformer (70% occupancy) reveals the canonical bidentate hy-
droxamate-Zn2+ coordination geometry. (c) Omit map of the minor TSA conformer (30% occu-
pancy) reveals unusual monodentate hydroxamate-Zn2+ coordination geometry. The Zn2+ ion ap-
pears as a large grey sphere; metal coordination and hydrogen bond interactions are shown as solid 
and dashed black lines, respectively.  
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coordination modes for the hydroxamate group of TSA, the monodentate hydroxamate-Zn2+ 
binding mode is only 0.5 kcal/mol higher in energy than the canonical bidentate hydroxamate-
Zn2+ binding mode. In structures determined at pH values ranging from 5.5 to 7.5, the occupancy 
ranges for the mono- and bidentate metal coordination geometries are 28-33% and 67-72%, re-
spectively, indicating no change in the monodentate:bidentate ratio as a function of the environ-
mental pH. 
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3.4 | Discussion 
3.4.1 – Structural Aspects of HDAC6-Inhibitor Selectivity 
Each component of an HDAC inhibitor – the Zn2+-binding group, the linker, and the 
capping group – contributes to the selectivity of inhibitor binding measured in biochemical assays. 
The key finding of the present study is that monodentate hydroxamate-Zn2+ coordination can be 
exploited by sterically bulky phenylhydroxamate inhibitors in the active site of HDAC6. The in-
hibitors HPB, ACY-1083, and HPOB each exhibit monodentate hydroxamate-Zn2+ coordination 
through their hydroxamate N–O– groups, with their hydroxamate C=O groups hydrogen bonded 
to a Zn2+-bound water molecule (Figure 3.6). The pan-HDAC inhibitor TSA (R-stereoisomer) 
engages in both bidentate and monodentate hydroxamate-Zn2+ coordination, as enabled by its 
comparatively slender linker group. The bidentate:monodentate ratio of 70:30 indicates a free en-
ergy difference of only 0.5 kcal/mol, so the monodentate hydroxamate-Zn2+ binding mode ob-
served exclusively for sterically bulky phenylhydroxamate inhibitors does not significantly com-
promise enzyme-inhibitor affinity. The energetically accessible monodentate binding mode can 
be exploited by inhibitors that are too bulky to bind more deeply in the HDAC6 active site as 
would be required for bidentate coordination. This binding mode appears to be unaffected by 
perturbations in pH, despite different possible protonation states of H574 in either mono- or 
bidentate binding, suggesting that this ratio is enforced by the structure of the inhibitor rather 
than variability in the protein environment. 
Interestingly, the secondary amino linker group of ACY-1083 donates a hydrogen bond 
directly to the hydroxyl group of S531 (Figure 3.3). S531 plays a key role in HDAC6-substrate 
recognition by accepting a hydrogen bond from the backbone NH group of the scissile acetyl-L-
lysine substrate.48 In class I enzymes such as HDAC8, D101 serves this role and accepts hydrogen  
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Figure 3.6 | Bidentate and monodentate hydroxamate–zinc binding modes 
Representation of the (a) bidentate and (b) monodentate Zn2+ binding modes observed for hydrox-
amate HDAC inhibitors.  
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bonds from both backbone NH groups flanking the scissile acetyl-L-lysine residue.73,110 While 
HPB lacks comparable functionality to make a direct interaction with S531, the hydroxyl group 
of its peptoid capping group forms a water-mediated hydrogen bond with S531 (Figure 3.2). Thus, 
direct or water-mediated hydrogen bonding with S531 is an interaction unique to the HDAC6 
active site that confers some measure of isozyme selectivity.  
  The capping group of each inhibitor significantly contributes to HDAC6 affinity and se-
lectivity. The capping group binds at the mouth of the active site cleft, and this region exhibits 
significant structural differences among the HDAC isozymes. In HDAC6, the L1 (H455-E465), 
L2 (M517-N536) and L7 (A706–Q716) loops can interact with inhibitor capping groups. The 
aromatic capping groups of HPB, ACY-1083, and HPOB pack primarily against the L1 loop; in 
addition, the capping group of Ricolinostat is sufficiently large to interact with both the L1 and 
L7 loops.  
  The L1 loops of HDAC6 and class I HDACs adopt different conformations that signifi-
cantly influence inhibitor binding (Figure 3.7). The phenyl group of the 260-fold selective inhib-
itor ACY-1083 packs tightly against the side chains of H463 and P464 in the L1 loop. Superpo-
sition of this complex with the structures of HDAC1, HDAC2, and HDAC3 complexed with 
their respective activating domains shows that the L1 loops of class I HDACs adopt different 
conformations that constrict their active sites relative to HDAC6.44,46 This would create a steric 
clash with the binding conformation of ACY-1083. A similar steric clash would result with the 
L1 loop of HDAC2.45 Thus, ACY-1083 binding to class I HDACs appears to be disfavored due 
to clashes between the large capping group and the L1 loop.  
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Figure 3.7 | Surface loops in HDACs 1, 2, 3, and 6 
Superposition of HDAC6 CD2 (pale blue) complexed with ACY-1083 (orange), HDAC1 (PDB 
4BKX), HDAC2 (PDB 4LY1), and HDAC3 (PDB 4A69). All class I HDACs are shown in 
shades of grey. The L1 and L2 loops are shown in shades of red, orange, and yellow for HDAC1, 
HDAC2, and HDAC3, respectively, and shades of blue for HDAC6. Corepressor proteins com-
plexed with HDAC1 and HDAC3, respectively MTA1 and NCOR2, are shown in green and 
appear to stabilize the L1 loop conformation. The inositol tetraphosphate (IP4) bound at the 
HDAC3–NCOR2 interface is also shown. A conserved proline residue is shown on each L1 loop 
to highlight the steric crowding that would occur upon ACY-1083 binding to the class I HDACs. 
The L1 loop is set back by ca. 1 Å in HDAC6 relative to the class I HDACs. The Zn2+ ion of 
HDAC6 is shown as a lavender sphere.  
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Ricolinostat has the largest capping group of the inhibitors shown in Table 1, and this cap 
binds in a cleft between the L1 and L7 loops of HDAC6. Superposition with HDAC3 shows a 
~1 Å difference in these loop conformations, resulting in a narrowed cleft that would be less ideal 
for Ricolinostat binding. The 12-fold HDAC6-selectivity of Ricolinostat arises solely from this 
capping group, since the flexible aliphatic linker and bidentate hydroxamate-Zn2+ binding mode 
are otherwise identical to those of the pan-HDAC inhibitor SAHA. 
3.4.2 – HDAC6–Nexturastat A Complex 
The 1.99 Å-resolution crystal structure of HDAC6 CD2 complexed with the HDAC6-
selective inhibitor Nexturastat A136 (NextA; Figure 3.8a) was recently reported.49 Curiously, de-
spite its structural resemblance to HPOB and HPOB as a bulky phenylhydroxamate derivative, 
NextA is reported to bind with an alternative monodentate hydroxamate-Zn2+ coordination ge-
ometry in which the hydroxamate carbonyl oxygen coordinates to Zn2+ with a Zn2+---O distance 
of 2.6 Å (Figure 3.8b). This separation is rather long for inner-sphere metal coordination. How-
ever, we inspected the electron density map generated with structure factor amplitudes and phases 
calculated from the final model of the enzyme-inhibitor complex deposited in the Protein Data 
Bank (PDB accession code 5G0I); we suggest that the map better accommodates monodentate 
hydroxamate-Zn2+ coordination by the hydroxamate N–O– group (Figure 3.8c). This binding 
mode refines with a Zn2+---O distance of 2.2 Å, which is more typical for an inner-sphere metal 
coordination interaction. Additionally, the hydroxamate C=O group accepts a hydrogen bond 
from the Zn2+-bound water molecule, as observed for HPOB,48 HPB (Figure 3.2), ACY-1083 
(Figure 3.3), and the minor conformer of TSA (Figure 3.5). Thus, we suggest that Figure 3.8c 
illustrates the preferred binding mode of NextA. 
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Figure 3.8 | Reinterpretation of the HDAC6–Nexturastat A complex (PDB 5G0I) 
(a) Structure of Nexturastat A (NextA) shown with the same color scheme as in Figure 1 (blue = 
linker, orange = capping group). (b) Simulated annealing omit map contoured at 2.5σ showing 
NextA (orange) bound to CD2 (grey) in monomer A of the structure as reported by Matthias and 
colleagues (PDB 5G0I). (c) Simulated annealing omit map contoured at 2.5σ for a reinterpreted 
model of NextA (orange) bound to CD2 (blue). The Zn2+ ion is shown as a grey sphere and the 
Zn2+-bound water molecule is shown as a small red sphere. Metal coordination and hydrogen bond 
interactions are shown as solid and dashed black lines, respectively.  
77 
 
 
3.5 | Summary & Conclusions 
Canonical bidentate hydroxamate-Zn2+ coordination was first observed for inhibitor bind-
ing to thermolysin,137 and exceptions are rarely observed.138 Here, we have outlined a new hydrox-
amate-Zn2+ binding mode exploited by bulky phenylhydroxamates in the active site of HDAC6: 
these inhibitors coordinate to Zn2+ through a monodentate hydroxamate N–O– group while the 
hydroxamate C=O group accepts a hydrogen bond from Zn2+-bound water. A 6-membered ring 
hydroxamate-Zn2+-H2O complex results, as summarized in Figure 3.6. The free energy of this 
novel Zn2+ binding mode is just 0.5 kcal/mol higher than that of the canonical bidentate hydrox-
amate-Zn2+ complex. This alternative Zn2+ binding mode can be exploited by bulky phenylhy-
droxamate inhibitors in the active site of HDAC6, even though the binding of these inhibitors 
would be disfavored in the more sterically constricted active sites of class I HDACs. Intriguingly, 
this alternative binding mode would disfavor the potential for the Zn2+-dependent Lossen rear-
rangement that could convert the hydroxamate moiety into a mutagenic isocyanate derivative.91 
  The linker groups of HDAC6-selective inhibitors can make direct or water-mediated hy-
drogen bonds with S531. This residue accepts a hydrogen bond from the backbone NH group of 
the acetyl-L-lysine substrate,48 and this interaction is unique to the HDAC6 active site. Thus, an 
inhibitor that targets this interaction will exhibit selectivity for binding to HDAC6. Finally, in-
teractions of inhibitor capping groups at the mouth of the HDAC6 active site reveal that structural 
differences in the L1 loop also contribute to isozyme selectivity. Thus, specific interactions of the 
Zn2+-binding group, linker, and capping group together contribute to selectivity for HDAC6 
binding.  
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Chapter 4 | Influence of Capping Groups on Inhibitor Binding 
Work presented here is reprinted from Porter, N.J.; Osko, J.D.; Diedrich, D.; Kurz, T.; Hooker, 
J.M.; Hansen, F.K.; Christianson, D.W. J. Med. Chem. 2018, 61, 8054-8060. Crystal structures 
of HDAC6 in complex with compounds 1, 2, and Bavarostat were determined by N.J.P. The 
HDAC6-3 complex was determined by J.D.O. Inhibitor 3 was synthesized by D.D. 
4.1 | Introduction 
  As mentioned in Section 3.1, the selective inhibition of histone deacetylase 6 (HDAC6) is 
a viable route to the treatment of a variety of clinical conditions. Selective inhibition of this en-
zyme, serving as the cytosolic tubulin deacetylase,139 can be achieved by designing hydroxamate 
inhibitors bearing substantial rigidity and steric bulk. 
  To better understand the structure–affinity and structure–selectivity relationships in 
HDAC6-inhibitor complexes, we determined X-ray crystal structures of catalytic domain 2 (CD2) 
of HDAC6 from Danio rerio (zebrafish) complexed with four different phenylhydroxamic acid-
based inhibitors at 1.47−2.20 Å resolution. These studies focused on the inhibition of CD2 and 
not catalytic domain 1 (CD1) because only CD2 exhibits broad-specificity catalytic activity;48 
moreover, it is this domain that is established to be the responsible for tubulin deacetylation.125 
Molecular structures of the phenylhydroxamate-based inhibitors are shown in Figure 4.1. Inhibi-
tors 1 and 2 contain large peptoid capping groups and exhibit better than 200-fold selectivity in 
comparison with HDAC2,140 whereas structurally related inhibitor 3 is essentially non-selective. 
Bavarostat (4) exhibits better than 16-fold selectivity in comparison with HDAC1, HDAC2, and 
HDAC3.141 Bavarostat is used as a brain-penetrant positron emission tomography (PET) probe 
for imaging HDAC6 in the central nervous system.141 
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These structural studies show that peptoid inhibitors 1–3 bind to HDAC6 with primarily 
monodentate hydroxamate-Zn2+ coordination geometry; however, Bavarostat (4) binds with ca-
nonical bidentate hydroxamate-Zn2+ coordination geometry. Comparisons with available struc-
tures of HDAC6-inhibitor complexes48,49,142 suggest that the hybridization of the linker benzylic 
nitrogen and the steric bulk of the capping group influence the denticity of hydroxamate-Zn2+ 
coordination. Interactions of the capping group in a pocket defined by the L1 loop further con-
tribute to selectivity for binding to HDAC6. 
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Figure 4.1 | Phenylhydroxamate-based HDAC6 inhibitors 
Phenylhydroxamate-based HDAC6 inhibitors and the corresponding selectivity data over the class 
I enzyme HDAC1. Literature values obtained from: aRef. 140; bRef. 141.  
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4.2 | Materials & Methods 
4.2.1 - Reagents.  
Chemicals used in buffer and crystallization conditions were obtained from Fisher, Milli-
pore Sigma, or Hampton Research and used without further purification. Inhibitors 1 and 2 were 
synthesized as reported.140 Bavarostat was synthesized as described.141 Inhibitor 3 was synthesized 
through a similar approach as used for the synthesis of inhibitors 1 and 2, except that benzyl iso-
cyanide was used as the isocyanide component and 4-(dimethylamino)benzoic acid was used as 
the carboxylic acid component in the Ugi four-component reaction. Product purity was confirmed 
to be greater than 95% based on RP-HPLC analysis. The compound characterization data of 
compound 3 are summarized below. 
N-(2-(Benzylamino)-2-oxoethyl)-4-(dimethylamino)-N-(4-(hydroxycarbamoyl)ben-
zyl)benzamide (3). Colorless solid; mp: 193 C; purity: 98.2 %. 1H NMR (300 MHz, DMSO-
d6):  = 11.20 (s, 1H), 9.03 (s, 1H), 8.60-8.32 (m, 1H), 7.83-7.66 (m, 2H), 7.46-7.14 (m, 9H), 
6.75-6.55 (m, 2H), 4.67 (s, 2H), 4.30 (d, J = 5.8 Hz, 2 H), 3.90 (s, 2H), 2.93 (s, 6H) ppm. 13C 
NMR (75 MHz, DMSO-d6):  = 171.7, 168.15, 164.0, 151.2, 140.8, 139.2, 131.7, 128.6, 128.3, 
127.3, 127.15, 127.0, 126.82, 126.86, 121.9, 110.95, 42.1, 39.7 ppm. Anal. Calcd. for 
C26H29N4O4: 461.2183 [M+H]+, found: 461.2182. 
4.2.2 - Inhibitory activities.  
The in vitro inhibitory activities (IC50 values) of compounds 1, 2, and 4 (Bavarostat) against 
HDAC isozymes have been previously reported.140,141 The in vitro inhibitory activities of com-
pound 3 against HDAC6 and HDAC1 were measured using a previously described protocol.143 
OptiPlate-96 black microplates (Perkin Elmer) were used with an assay volume of 50 µL. A total 
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of 5 µL 3 or control, diluted in assay buffer [50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM 
KCl, 1 mM MgCl2, 0.1 mg/mL BSA], were incubated with 35 µL of the fluorogenic substrate 
ZMAL (Z-Lys(Ac)-AMC)144 (21.43 µM in assay buffer) and 10 µL of human recombinant 
HDAC1 (BPS Bioscience, Catalog #50051) or HDAC6 (BPS Bioscience, Catalog #50006) at 37 
°C. After an incubation time of 90 min, 50 µL of 0.4 mg/mL trypsin in trypsin buffer [50 mM 
Tris-HCl (pH 8.0), 100 mM NaCl] were added, followed by further incubation at 37 °C for 30 
min. Fluorescence was measured with an excitation wavelength of 355 nm and an emission wave-
length of 460 nm using a Fluoroskan Ascent microplate reader (Thermo Scientific). Compound 
3 was evaluated in duplicate in two independent experiments. 
4.2.3 - Crystallization. 
Catalytic domain 2 of HDAC6 from Danio rerio (henceforth simply “HDAC6”) was re-
combinantly expressed in the E. coli BL21 (DE3) strain using the His6-MBP-TEV-HDAC6-
pET28a(+) vector and purified as previously described.48,142 All HDAC6-inhibitor complexes were 
crystallized in sitting drops by the vapor diffusion method at 4˚C.  
For cocrystallization of the HDAC6–1 complex, a 5 µL drop of protein solution [5 mg/mL 
HDAC6, 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.5), 100 
mM KCl, 5% glycerol (v/v), 1 mM tris(2-carboxyethyl)phosphine (TCEP), saturated 1 (approxi-
mately 0.5 mM), and 5% DMSO (v/v)] was added to 5 µL of precipitant solution [400 mM NaF 
and 15% polyethylene glycol (PEG) 3,350 (w/v)] and equilibrated against 500 µL of precipitant 
solution. Crystals appeared within 2 days. 
For cocrystallization of the HDAC6–2 complex, a 350 nL drop of protein solution [10 
mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM TCEP, 
saturated 2 (approximately 1.0 mM), and 5% DMSO (v/v)] was added to 350 nL of precipitant 
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solution [2% tacsimate (pH 6.0; w/v), 0.1 M BisTris (pH 6.5), and 20% PEG 3,350 (w/v)] and 
equilibrated against 80 µL of precipitant solution. Crystals appeared within 2 days. 
For cocrystallization of the HDAC6–3 complex, a 350 nL drop of protein solution [10 
mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM TCEP, 
saturated 3 (approximately 0.5 mM), and 5% DMSO (v/v)] was added to 350 nL of precipitant 
solution [0.2 M ammonium tartrate dibasic pH 7.0 and 20% PEG 3,350 (w/v)] and equilibrated 
against 80 µL of precipitant solution. Crystals appeared within 2 days. 
For cocrystallization of the HDAC6–4 (Bavarostat) complex, a 350 nL drop of protein 
solution [10 mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM 
TCEP, saturated Bavarostat (approximately 0.5 mM), and 5% DMSO (v/v)] was added to 350 
nL of precipitant solution [200 mM L-proline, 100 mM HEPES (pH 7.5), and 24% PEG 1,500 
(w/v)] and equilibrated against 80 µL of precipitant solution. Crystals appeared within 2 days. 
All crystals were soaked in a cryoprotectant solution containing mother liquor supple-
mented with 20% ethylene glycol prior to flash-cooling in liquid nitrogen. 
4.2.4 - Data collection and structure determination. 
X-ray diffraction data for HDAC6 complexes with 1 and 2 were collected on NE-CAT 
beamline 24-ID-E at the Advanced Photon Source, Argonne National Lab. Diffraction data were 
collected from crystals of the HDAC6–3 and HDAC6–4 complexes on beamline 9-2 at the Stan-
ford Synchrotron Radiation Laboratory (SSRL), Stanford University. Data were indexed and in-
tegrated using iMosflm103 and data scaling was carried out using Aimless in the CCP4 program 
suite.104 
The atomic coordinates of unliganded HDAC6 (PDB 5EEM)48 were used as a search 
model to phase each crystal structure by molecular replacement using the program Phaser.105 
84 
 
Atomic models were built and manipulated using the graphics program Coot106 and crystallo-
graphic refinement was executed using Phenix.107 Inhibitor molecules were built into well-defined 
electron density in later rounds of refinement. The quality of each model was assessed using 
MolProbity108 and PROCHECK.109 Data collection and refinement statistics are recorded in Ta-
ble 4.1. 
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Table 4.1 | Structural statistics for HDAC6 complexes with bulky inhibitors 
Complex 1 2 3 Bavarostat 
Unit Cell 
Space group P21 P21 P21 P65 
a, b, c (Å) 55.1, 82.5, 89.0 78.5, 95.2, 98.0 78.6, 95.5, 98.3 97.2, 97.2, 78.9 
a, b, g (˚) 90.0, 98.6, 90.0 90.0, 98.9, 90.0 90.0, 98.6, 90.0 90.0, 90.0, 120.0 
Data Collection 
Wavelength (Å) 0.97918 0.97918 1.18076 0.97946 
Resolution (Å) 60.21–2.10 54.05–1.47 48.57–2.20 42.10–1.98 
Total / unique no. of 
reflections 154,035 / 45,494 899,877 / 238,509 406,680 / 21,942 282,074 / 29,613 
Rmergea,b 0.236 (1.266) 0.129 (0.723) 0.228 (0.764) 0.312 (1.740) 
Rpima,c 0.142 (0.735) 0.077 (0.428) 0.102 (0.371) 0.106 (0.590) 
CC1/2a,d 0.967 (0.545) 0.989 (0.594) 0.987 (0.721) 0.990 (0.655) 
I/s(I)a 5.8 (3.1) 8.2 (2.8) 7.0 (2.6) 8.0 (1.9) 
Redundancya 3.4 (3.5) 3.8 (3.8) 5.8 (5.0) 9.5 (9.6) 
Completeness (%)a 98.8 (98.8) 98.9 (98.7) 96.0 (92.6) 100.0 (100.0) 
Refinement 
No. of reflections 
used in refinement / 
test set 
45,551 / 4,544 238,405 / 23,692 69,939 / 6,728 29,563 / 2,924 
Rworka,e 0.176 (0.229) 0.148 (0.199) 0.188 (0.239) 0.168 (0.235) 
Rfreea,e 0.203 (0.265) 0.170 (0.229) 0.223 (0.301) 0.216 (0.273) 
No. of nonhydrogen 
atoms:     
protein 5,534 11,321 11,109 2,805 
ligand 70 248 168 60 
solvent 433 1861 193 222 
Average B-factors 
(Å2)     
protein 16 10 18 22 
ligand 19 15 21 32 
solvent 24 24 17 29 
Root-mean-square 
deviation from ideal 
geometry 
    
bonds (Å) 0.002 0.009 0.002 0.004 
angles (˚) 0.6 1.0 0.6 0.7 
Ramachandran plot 
(%)f     
favored 97.3 98.0 96.1 96.8 
allowed 2.7 2.0 3.9 3.2 
PDB accession code 6DVL 6DVM 6DVN 6DVO 
aValues in parentheses refer to data in the highest shell. bRmerge = ∑hkl∑i|Ii,hkl − ⟨I⟩hkl|/∑hkl∑i Ii,hkl, where ⟨I⟩hkl is the average 
intensity calculated for reflection hkl from replicate measurements. cRp.i.m.= (∑hkl(1/(N-1))1/2∑i|Ii,hkl − ⟨I⟩hkl|)/∑hkl∑i Ii,hkl, 
where ⟨I⟩hkl is the average intensity calculated for reflection hkl from replicate measurements and N is the number of 
reflections dPearson correlation coefficient between random half-datasets. eRwork = ∑||Fo| − |Fc||/∑|Fo| for reflections 
contained in the working set. |Fo| and |Fc| are the observed and calculated structure factor amplitudes, respectively. Rfree 
is calculated using the same expression for reflections contained in the test set held aside during refinement. fCalculated 
with PROCHECK.109  
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4.3 | Results and Discussion 
The 2.10 Å resolution structure of the HDAC6–1 complex reveals monodentate hydrox-
amate-Zn2+ coordination in both monomers in the asymmetric unit (Figure 4.2a). Selected inter-
atomic distances are recorded in Table 4.2. The phenyl linker is nestled in the aromatic crevice 
formed by F583 and F643 with average inter-ring separations of 3.5 Å each. The peptoid carbonyl 
is oriented away from “gatekeeper” residue S531 in the L2 loop48 and accepts a hydrogen bond 
from the guanidinium group of R601 in an adjacent monomer. This places the dimethylphenyl 
substituent in van der Waals contact with the side chains of L1 loop residues H463 and P464, 
which define a small pocket designated the “L1 loop pocket”. The cyclohexylamide carbonyl forms 
hydrogen bonds with two water molecules, one of which interacts with the backbone carbonyl of 
A641 while the other forms a hydrogen bond with another water molecule that interacts with Zn2+ 
ligand H614. The cyclohexyl moiety is oriented away from the enzyme surface, packing against 
the side chain of R736 in the adjacent monomer in the crystal lattice. 
The crystal structure of the HDAC6–2 complex determined at 1.47 Å resolution reveals a 
monodentate hydroxamate-Zn2+ binding mode in monomers A, C, and D in the asymmetric unit 
generally similar to that of compound 1; selected interatomic distances are recorded in Table 1. In 
monomer B, electron density is consistent with a mixture of monodentate and bidentate hydrox-
amate-Zn2+ binding modes with refined occupancies of 0.63 and 0.37, respectively (Figure 4.2b). 
The lower occupancy bidentate conformation exhibits Zn2+---O distances of 2.5 Å for the hy-
droxamate C=O and 2.2 Å for the hydroxamate N–O– group.  
Inter-ring separations between the phenyl linker of 2 and the side chains of F583 and F643 
are 3.3 Å and 3.9 Å, respectively, and the capping group adopts an essentially identical confor-
mation for both metal-binding modes. The peptoid carbonyl is oriented away from the enzyme 
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Figure 4.2 | Polder omit maps of bulky hydroxamates complexed with HDAC6 
Polder omit maps (green mesh) contoured at 3.0σ for compounds (a) 1 (orange), (b) 2 (orange/pur-
ple), (c) 3 (yellow), and (d) Bavarostat (blue) complexed with HDAC6 (white). The catalytic Zn2+ 
ion appears as a gray sphere; metal coordination and hydrogen bond interactions are shown as solid 
and dashed black lines, respectively. Atoms from a symmetry-related molecule in the crystal lattice 
are shown with dark-gray carbon atoms. In b, the monodentate hydroxamate conformation of 2 is 
shown in orange and the bidentate conformation is shown in purple. The binding of 1 (a) and 3 (c) 
illustrates exclusive monodentate hydroxamate-Zn2+ coordination; the binding of 4 (Bavarostat) 
(d) illustrates exclusive bidentate hydroxamate-Zn2+ coordination.  
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Table 4.2 | Average interatomic distances in monodentate inhibitor complexes (Å) 
Interatomic  
Measurement 
Inhibitor 
1 2 3 
N–O–---Zn2+ 2.1 1.8 2.0 
H2O---Zn2+ 2.1 2.0 2.2 
C=O---OH2 2.8 2.7 2.7 
O–---O (Y745) 2.5 2.8 2.8 
H2O---N (H573) 2.6 2.6 2.4 
H2O---N (H574) 2.9 2.9 2.9 
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surface toward bulk solvent. The dimethylaniline group resides in the L1 loop pocket, and its 
nitrogen atom makes a van der Waals contact with P464. Interestingly, crystal packing places the 
dimethylaniline moieties of separate inhibitor molecules adjacent to each other, such that they 
form a staggered p-stacking interaction with a ring separation distance of 3.9 Å. The tolylamide 
carbonyl interacts with Zn2+ ligand H614 through two hydrogen bonded water molecules, as ob-
served for compound 1. The tolyl moiety is accordingly oriented away from the enzyme surface 
and makes a van der Waals contact with the dimethylaniline methyl group of an inhibitor bound 
to an adjacent monomer in the crystal lattice. 
The crystal structure of the HDAC6–3 complex determined at 2.20 Å resolution largely 
resembles that of the HDAC6–2 complex. All four monomers in the asymmetric unit uniformly 
adopt monodentate hydroxamate-Zn2+ coordination geometry (Figure 4.2c, Table 4.2). The phe-
nyl linker resides in the aromatic crevice and is 3.3 Å and 4.0 Å away from the phenyl groups of 
F583 and F643, respectively. The peptoid carbonyl is oriented away from the protein surface and 
out toward bulk solvent. As in the HDAC6–2 complex, the dimethylaniline group resides in the 
L1 loop pocket. The dimethylaniline groups in adjacent monomers form staggered p-stacking 
interactions with a ring separation of 3.8 Å. The benzylamide carbonyl engages in the same sol-
vent-mediated interaction with Zn2+ ligand H614 as observed for the binding of compound 2. 
The benzyl moiety of compound 3 also makes a van der Waals contact with the dimethylaniline 
group of another inhibitor molecule bound to an adjacent monomer in the crystal lattice.  
The crystal structure of the HDAC6–4 (Bavarostat) complex determined at 1.98 Å reso-
lution, containing only one monomer in the asymmetric unit, clearly reveals canonical bidentate 
hydroxamate-Zn2+ coordination geometry with Zn2+---O separations of 2.2 and 2.0 Å, respec-
tively, for the hydroxamate C=O and N–O– groups (Figure 4.2d). The catalytic histidine residues, 
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H573 and H574, form hydrogen bonds with the hydroxamate N–O– and NH groups (N573---O 
separation = 2.5 Å and N574---N separation = 2.8 Å). The Y745 phenol oxygen hydrogen bonds 
with the hydroxamate carbonyl (O---O separation = 2.4 Å). The 2-fluorophenyl linker is situated 
in the aromatic crevice such that the fluorine atom is 3.3 Å from the side-chain methylene group 
of S531, 3.1 Å from the Ca atom of G582, 3.6 Å from the side chain of F583, and 3.1 Å from 
the side chain of F643. The benzylic tertiary amine is pyramidalized such that the lone pair on the 
nitrogen is oriented away from the side chain of gatekeeper residue S531, which revises a prior 
prediction.141 Instead, this nitrogen is oriented toward bulk solvent. The adamantyl capping group 
is nestled in the L1 loop pocket. 
4.3.1 – The HDAC6 L1 loop pocket.  
As the structures of HDAC6 complexed with compounds 1, 2, and 3 are compared, com-
mon features are evident for the binding of inhibitor capping groups. First, capping groups are 
similarly oriented, in that the smaller peptoid substituent (dimethylphenyl for 1, dimethylaniline 
for 2 and 3) sits in the L1 loop pocket while the larger peptoid substituent is oriented away from 
the protein surface. Curiously, the crystal structure of isolated compound 1 (CSD ID: 
GADYOC)140 exhibits a cis peptoid conformation, whereas it exhibits a trans-peptoid confor-
mation in its complex with HDAC6 (Figure 4.3a). The lower free energy difference between pep-
toid conformers presumably enables cis-trans isomerism to optimize the fit of the enzyme-inhibi-
tor complex. The association of the smaller peptoid substituent with the L1 loop pocket thus 
appears to direct the peptoid conformation (Figure 4.3b). Notably, the adamantyl group of Bava-
rostat is similarly positioned in the L1 loop pocket (Figure 4.3c), as are cap substituents of other 
HDAC6-selective inhibitors.49,142 Taken together, these data indicate that the L1 loop pocket of 
HDAC6 provides a binding site for hydrophobic capping groups. Key residues defining this  
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Figure 4.3 | Binding of compound 1 to HDAC6 and packing in the L1 loop pocket 
(a) Stereo superposition of crystal structures of free (light blue) and HDAC6-complexed (orange) 
conformations of compound 1. The phenyl linkers of these models have been aligned, highlighting 
conformational differences in the capping groups. (b) Binding of compound 1 to HDAC6 (light 
blue) with the dimethylphenyl group of the inhibitor cap packing against the L1 loop (H455–E465; 
yellow). (c) Binding of 4 (Bavarostat, blue) to HDAC6 viewed from a similar orientation to that 
shown in (b).  
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pocket (H463, P464, F583, and L712) are strictly conserved between human HDAC6, the actual 
drug target, and zebrafish HDAC6, the ortholog used for X-ray crystallographic studies.  
Notably, the L1 loop of HDAC6 is relatively rigid. Accordingly, the rigid, pre-formed 
nature of the L1 loop pocket presumably contributes to the selectivity of inhibitor binding to 
HDAC6 by minimizing the entropic cost of inhibitor binding site organization. Indeed, the bind-
ing of selective inhibitors to HDAC6 is generally characterized by entropy gain.145 
These results further support the hypothesis that interactions with the L1 loop are im-
portant for HDAC6–inhibitor selectivity. In the class I HDACs 1, 2, and 3, the L1 loop is shifted 
by approximately 1 Å relative to HDAC6, constricting the substrate binding pocket, and the L1 
loop is buttressed when the enzyme is activated through the binding of corepressor and inositol 
tetraphosphate.44–46 This conformational difference would perturb the binding of a sterically bulky 
inhibitor capping group, thus rendering the inhibitor ineffective. We suggest that this effect ac-
counts for the selectivity of Bavarostat for inhibition of HDAC6 relative to the class I HDACs 1, 
2, and 3 (Figure 4.1).141 
Surprisingly, inhibitor 3 binds with comparable affinity to HDAC6 compared with inhib-
itor 2, but 3 is much less selective than 2 with respect to inhibition of class I HDACs. We attribute 
this to the additional flexibility conferred by the benzylic substituent of 3 compared with the more 
rigid tolyl substituent of 2. The additional bulk and flexibility of 3 presumably enables binding to 
the more constricted active sites of class I HDACs, as exemplified for HDAC3 in Figure 4.4.  
4.3.2 - Capping group influence on hydroxamate-Zn2+ denticity.  
Compared to other HDACs, the substrate binding groove of HDAC6 is wider (Figure 
4.4). As a result, sterically bulky phenylhydroxamates can readily access the catalytic Zn2+ ion of 
HDAC6 but they cannot interact as easily with the catalytic Zn2+ ion of class I HDAC isozymes.  
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Figure 4.4 | Active site constriction in HDAC3 relative to HDAC6 
Active site surfaces of (a) HDAC6 in its complex with inhibitor 1, and (b) HDAC3 (PDB 4A69) 
with inhibitor 1 modeled in the active site based on structural alignment with the HDAC6–1 com-
plex. Zn2+ ions appear as grey spheres and metal coordination interactions are represented by solid 
yellow lines. The active site of HDAC6 is wider and more readily accommodates phenylhydrox-
amate inhibitors with bulky para-substituted substituents.  
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However, the molecular features that distinguish monodentate versus bidentate hydroxamate-Zn2+ 
coordination in the HDAC6 active site are less clear. 
Insight regarding this phenomenon can be acquired from studying the 22 unique hydrox-
amate based crystal structures of HDAC6–inhibitor complexes determined to date, including the 
4 structures reported here.48,49,142,143,145–147 Of these, 11 display canonical bidentate binding, 9 dis-
play monodentate binding, and 2 exhibit fractional occupancy of each conformation in one crys-
tallographic monomer. Bidentate metal coordination is generally observed for inhibitors that pos-
sess either flexible aliphatic linkers or aromatic linkers lacking a capping group. Addition of bulky 
and/or rigid capping groups to a phenylhydroxamate inhibitor generally leads to monodentate 
hydroxamate-Zn2+ coordination, but the steric bulk must be located close to the phenylhydrox-
amate moiety. Specifically, the capping group must branch at the second atom away from the 
phenyl ring, and both substituents at the branch must be bulky. While Bavarostat (4) contains a 
bulky adamantyl cap as one substituent at the amino branch of the capping group, the second 
substituent is only a methyl group, which thus enables the phenylhydroxamate to more closely 
approach the catalytic Zn2+ ion to achieve bidentate coordination geometry. Another feature that 
may enable binding flexibility for Bavarostat is the sp3-hybridized nitrogen atom of the tertiary 
amino group itself. In contrast with the planar sp2-hybridized peptoid nitrogen atoms of inhibitors 
1–3, the tertiary amino nitrogen of Bavarostat can rapidly invert between two pyramidal stereoi-
somers as needed to optimize enzyme-inhibitor interactions. 
Compounds 1–3 contain relatively rigid peptoid moieties with two bulky substituents 
branching at the second atom away from the para-substituted phenylhydroxamate. Apart from 
one of four monomers in the HDAC6–2 complex, these inhibitors bind with monodentate hy-
droxamate-Zn2+ coordination geometry. Taking into account multiple independent copies of the 
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enzyme-inhibitor complex with 2 in the asymmetric unit, the overall monodentate:bidentate ratio 
is 3.6:0.4. This suggests that, for compound 2, monodentate coordination is ~1.3 kcal/mol more 
stable as observed in the crystal structure. In comparison, the mixture of monodentate and biden-
tate conformers in the 1.05 Å-resolution structure of the HDAC6–R-TSA complex suggested 
that bidentate coordination was 0.5 kcal/mol more stable.142 Therefore, it appears that the steric 
bulk and rigidity of inhibitor capping groups modulate the equilibrium between bidentate and 
monodentate hydroxamate-Zn2+ coordination and thereby direct the metal ion coordination 
mode. 
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4.4 | Conclusions 
The high-resolution crystal structures of HDAC6 complexes with bulky peptoid inhibitors 
1–3 as well as Bavarostat (4) highlight the importance of the L1 loop pocket in accommodating 
large hydrophobic groups. This pocket is largely defined by H463, P464, F583, and L712, and 
these residues are conserved between human HDAC6, the actual human drug target, and 
zebrafish HDAC6, the ortholog used for X-ray crystal structure determinations. Each inhibitor 
studied is a phenylhydroxamate containing a capping group that branches at the second atom away 
from the aromatic ring. Analysis of HDAC6-inhibitor complexes suggests that if both branching 
substituents are sterically bulky, then the inhibitor will bind with monodentate hydroxamate-Zn2+ 
coordination geometry; if only one substituent is bulky, or if there is no substituent at all (i.e., a 
simple phenylhydroxamate26), then the inhibitor will bind with bidentate hydroxamate-Zn2+ co-
ordination geometry. Future studies will allow us to further clarify structure-affinity and selectivity 
relationships for inhibitor binding to HDAC6. 
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Chapter 5 | Entropy Contributes to HDAC6-Selective Inhibition 
Work presented here is reprinted from Porter, N.J.; Wagner, F.F.; Christianson, D.W. Biochemis-
try 2018, 57, 3916-3924. 
 
5.1 | Introduction 
  As discussed in chapters 3 and 4, typical HDAC inhibitors consist of a zinc-binding group 
such as a hydroxamate, a capping group capable of interacting with residues in the active site cleft, 
and a linker group connecting the two. Appreciable selectivity for HDAC6 is observed for inhib-
itors containing aromatic linker groups and bulky capping groups such as Tubastatin A,129 N-
hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-oxoethyl)benzamide (HPOB),130 N-hydroxyl-
4-[(N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide)] (HPB),131 and Nexturastat.136 
The previously discussed crystal structures of HDAC6 complexed with some of these inhibitors 
have revealed that these sterically bulky inhibitors exploit an unusual monodentate hydroxamate-
Zn2+ coordination mode that is nearly isoenergetic with the more commonly observed bidentate 
hydroxamate-Zn2+ coordination mode.48,49,142 This binding mode results from steric constrictions 
in the HDAC6 active site by the L1, L2, and L6 loops that prevent phenylhydroxamates with 
bulky capping groups from making a closer interaction with the catalytic Zn2+ ion. However, sim-
ple “capless” inhibitors retain nanomolar potency and 10-fold or greater selectivity for HDAC6 
relative to class I HDACs based on IC50 assays (Figure 5.1).148 Therefore, the bulky capping group 
is not the sole determinant of selectivity. What, then, determines the isozyme selectivity of these 
low-molecular weight, capless inhibitors? 
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  To address this question, we determined X-ray crystal structures of the high-activity CD2 
domain from Danio rerio HDAC6 (henceforth simply “HDAC6”) complexed with the capless 
inhibitors phenylhydroxamate (1), cyclohexenylhydroxamate (2), cyclohexylhydroxamate (3), and 
cyclopentenylhydroxamate (4) (Figure 5.1). These compounds have been previously profiled as 
HDAC6 inhibitors with sub-micromolar potencies and selectivites of up to 36-fold based on IC50 
measurements made by Wagner and colleagues.148 To better understand selective HDAC inhibi-
tion by these compounds, we also performed thermodynamic measurements of enzyme-inhibitor 
complexation using isothermal titration calorimetry (ITC). These studies together reveal that a 
favorable entropy of binding contributes to the inhibitory selectivity towards the class IIb enzyme 
HDAC6 over the class I enzyme HDAC8. 
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Figure 5.1 | Capless HDAC6-selective inhibitors 
Structure and selectivity of capless cyclohydroxamate inhibitors that are selective for HDAC6 over 
HDAC8 in IC50 assays. Literature values obtained from Ref. 148.  
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5.2 | Materials and Methods 
5.2.1 – Reagents 
In general, chemicals used in buffers and crystallization conditions were purchased from 
Fisher, Millipore Sigma, or Hampton Research and used without further purification. Com-
pounds 1–4 were synthesized as described.148 
5.2.2 – Protein Preparation 
Catalytic domain 2 from Danio rerio HDAC6 (herein designated simply “HDAC6”) was 
recombinantly expressed using His6-MBP-TEV-HDAC-pET28a(+) vectors and purified as pre-
viously described with minor modifications.142 Briefly, HDAC6 was expressed using E. coli BL21 
(DE3) (Stratagene) grown in 2x YT medium under the selection of 50 mg/mL kanamycin. Ex-
pression was induced with 250 µM isopropyl b-L-1-thiogalactopyranoside (IPTG; Gold Biotech-
nology) along with the addition of 500 µM ZnCl2 at 18˚C. Cells were collected by centrifugation 
and stored at -80 ˚C prior to purification. 
  Pellets were thawed and resuspended in purification buffer [50 mM 4-(2-hydroxyethyl)-
1-piperazine-ethanesulfonic acid (HEPES; pH 7.5), 300 mM KCl, 10% glycerol (v/v), 1 mM 
tris(2-carboxyethyl)phosphine (TCEP)] and lysed by sonication. Lysate was clarified by centrifu-
gation at 38,000g for 1 hour at 4 ˚C. The supernatant was applied to amylose resin (New England 
BioLabs). His6-MBP-TEV-HDAC6 fusion protein was either eluted using 10 mM maltose or 
digested on-column with 2 mg/mL recombinant His-TEV protease. Eluted fusion protein was 
digested using recombinant His-TEV protease overnight at 4 ˚C while dialyzing in purification 
buffer. The digest was applied to an equilibrated Ni-NTA agarose column (Qiagen) to remove 
His-MBP and His-TEV, which were subsequently eluted using a 0–500 mM imidazole gradient 
in purification buffer. The HDAC6-containing fractions were concentrated to <10 mL over a 
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10,000 Da molecular weight cut-off filter unit (Millipore) and applied to a HiLoad Superdex 
200pg column in size exclusion buffer [50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol 
(v/v), 1 mM TCEP]. Fractions containing pure HDAC6 were identified using SDS-PAGE, 
pooled, and concentrated to 14–20 mg/mL. Protein was flash-frozen in liquid nitrogen and stored 
at -80 ˚C prior to usage. 
  HDAC8 was expressed and purified as previously described,73 with minor modifications. 
Briefly, a 500 mL culture [Lysogeny Broth (LB) at 100 µg/mL ampicillin] was grown overnight 
at 37 ˚C with shaking at 250 rpm. Aliquots of this culture (30 mL) were used to inoculate 12 ´ 1 
L of M9 minimal medium supplemented with 100 µg/mL ampicillin. Cells were grown until the 
OD600 » 1.0, at which point the temperature was reduced to 18 ˚C. After cooling for 30 min, 
protein expression was induced with 100 µM ZnCl2 and 100 µM IPTG. Protein was expressed 
overnight and pellets were harvested via centrifugation and stored at -80 ˚C until they were puri-
fied. The purification was carried out as previously described using a Co2+-TALON® column fol-
lowed by size exclusion chromatography.73 All protein was concentrated to 10-20 mg/mL, flash-
frozen in liquid nitrogen, and stored at -80 ˚C until use. 
 5.2.3 – Crystallization 
All HDAC6-inhibitor complexes were crystallized in sitting drops by the vapor diffusion 
method at 4 ˚C. 
  For cocrystallization of the HDAC6–1 and HDAC6–2 complexes, a 350 nL drop of pro-
tein solution [5 mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 
mM TCEP, 5 mM 1 or 2, and 5% dimethyl sulfoxide (DMSO) (v/v)] was added to 350 nL of 
precipitant solution [200 mM ammonium chloride and 20% PEG 3,350] and equilibrated against 
80 µL of precipitant solution. Rhomboid plate crystals appeared within 2 days. 
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   For cocrystallization of the HDAC6–3 complex, a 2 µL drop of protein solution [2.5 
mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM TCEP, 5 
mM 3, and 5% dimethyl sulfoxide (DMSO) (v/v)] was added to a 2 µL drop of precipitant solution 
[40 mM sodium citrate/60 mM Bis-Tris propane (pH 6.4) and 25% PEG 3,350] and was streak-
seeded with a seed stock of crushed HDAC6–3 crystals previously generated under the same con-
ditions but with 5 mg/mL enzyme in the protein solution. This was equilibrated against 80 µL of 
precipitant solution. Rhomboid plate crystals appeared within 2 days. 
  For cocrystallization of the HDAC6–4 complex, a 350 nL drop of protein solution [5 
mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM TCEP, 5 
mM 4, and 5% dimethyl sulfoxide (DMSO) (v/v)] was added to 350 nL of precipitant solution 
[200 mM ammonium tartrate dibasic and 20% PEG 3,350] and equilibrated against 80 µL of 
precipitant solution. Rhomboid plate crystals appeared within 2 days. 
  All crystals were soaked in a cryoprotectant solution containing mother liquor supple-
mented with 20% ethylene glycol prior to flash-cooling in liquid nitrogen. 
5.2.4 – Data collection and structure determination 
X-ray diffraction data were collected from crystals on beamline 9-2 at the Stanford Syn-
chrotron Radiation Laboratory (SSRL), Stanford University for the HDAC6 complexes with in-
hibitors 1, 2, and 3. Diffraction data for the HDAC6–4 complex were collected on beamline 17-
ID-2 (FMX) at the National Synchrotron Light Source II (NSLS2), Brookhaven National Lab. 
Data were indexed and integrated using iMosflm103 and scaled using Aimless in the CCP4 pro-
gram suite.104 Data collection statistics are recorded in Table 1. Each crystal structure was solved 
by molecular replacement using the atomic coordinates of unliganded HDAC6 (PDB 5EEM)48 
as a search model for rotation and translation function calculations using the program Phaser.105 
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Atomic models were constructed and modified using the graphics program Coot106 and crystallo-
graphic structure refinement was performed using Phenix.107 Inhibitor molecules were added when 
clearly resolved electron density was observed for each. Occasionally, maps displayed spurious elec-
tron density peaks that could not be satisfactorily modeled by ordered solvent, ligand, or cryopro-
tectant, in which case these peaks were left uninterpreted. The quality of each model was assessed 
using MolProbity108 and PROCHECK.109 Final refinement statistics are recorded in Table 5.1. 
 5.2.5 – Isothermal Titration Calorimetry 
Thermograms were measured for inhibitor binding to HDAC6 and HDAC8 using a Mi-
croCal iTC 200 isothermal titration calorimeter (GE Healthcare). For each compound, 300 µM 
inhibitor was titrated against 30 µM enzyme in size exclusion buffer with 0.3% DMSO for com-
pounds 1–4. Thirty-eight 1-µL injections were made over 80 min. Integration, curve fitting, and 
figure generation were performed using Origin (OriginLab, Northampton, MA). 
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Table 5.1 | Structural statistics for HDAC6 complexes with capless cyclohydroxamates 
Complex 
1 
(phenylhydroxamate) 
2 
(cyclohexenyl- 
hydroxamate) 
3 
(cyclohexyl- 
hydroxamate) 
4 
(cyclopentenyl- 
hydroxamate) 
Unit Cell 
Space group P212121 P212121 P212121 P212121 
a, b, c (Å) 74.8, 91.9, 96.4 74.7, 91.8, 96.5 74.7, 91.8, 96.5 74.8, 92.0, 96.6 
a, b, g (˚) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Data Collection 
Wavelength (Å) 0.97946 0.97946 0.97946 0.97933 
Resolution (Å) 48.2 – 1.62 59.08 – 1.24 96.60 – 2.03 96.64 – 1.70 
Total / unique no. of 
reflections 528011 / 84908 1156727 / 188513 271026 / 43532 507763 / 74006 
Rmergea,b 0.189 (0.816) 0.101 (0.593) 0.228 (0.538) 0.224 (1.558) 
Rpima,c 0.082 (0.346) 0.044 (0.257) 0.099 (0.229) 0.91 (0.670) 
CC1/2a,d 0.969 (0.682) 0.997 (0.871) 0.988 (0.850) 0.991 (0.605) 
I/s(I)a 6.7 (2.2) 10.0 (3.0) 6.3 (3.6) 8.6 (3.4) 
Redundancya 6.2 6.1 (6.2) 6.2 (6.4) 6.9 (6.3) 
Completeness (%)a 99.5 (99.7) 99.7 (99.9) 99.8 (100) 100 (100) 
Refinement 
No. of reflections 
used in refinement / 
test set 
84,783 / 8,378 188,358 / 18,683 43,445 / 4,284 73,824 / 7,278 
Rworka,e 0.170 (0.262) 0.127 (0.177) 0.176 (0.221) 0.169 (0.220) 
Rfreea,e 0.219 (0.338) 0.153 (0.219) 0.223 (0.266) 0.194 (0.256) 
No. of nonhydrogen 
atoms:     
protein 5721 5838 5563 5689 
ligand 74 125 26 60 
solvent 764 935 648 654 
Average B-factors 
(Å2)     
protein 11 10 10 10 
ligand 17 20 7 19 
solvent 23 24 17 23 
Root-mean-square 
deviation from ideal 
geometry 
    
bonds (Å) 0.006 0.008 0.003 0.003 
angles (˚) 0.8 1.0 0.6 0.7 
Ramachandran plot 
(%)f     
favored 97.75 97.61 97.60 97.61 
allowed 2.25 2.39 2.40 2.39 
PDB accession code 6CSR 6CSP 6CSQ 6CSS 
aValues in parentheses refer to data in the highest shell. bRmerge = ∑hkl∑i|Ii,hkl − ⟨I⟩hkl|/∑hkl∑i Ii,hkl, where ⟨I⟩hkl is the average 
intensity calculated for reflection hkl from replicate measurements. cRp.i.m.= (∑hkl(1/(N-1))1/2∑i|Ii,hkl − ⟨I⟩hkl|)/∑hkl∑i Ii,hkl, 
where ⟨I⟩hkl is the average intensity calculated for reflection hkl from replicate measurements and N is the number of 
reflections dPearson correlation coefficient between random half-datasets. eRwork = ∑||Fo| − |Fc||/∑|Fo| for reflections 
contained in the working set. |Fo| and |Fc| are the observed and calculated structure factor amplitudes, respectively. 
Rfree is calculated using the same expression for reflections contained in the test set held aside during refinement. fCal-
culated with PROCHECK.109  
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5.3 | Results and Discussion 
5.3.1 – X-ray crystallography 
  Crystal structures were solved and refined with Rwork and Rfree values ranging 0.127–0.176 
and 0.153–0.223, respectively (Table 5.1). For each HDAC6–inhibitor complex, there are no ma-
jor conformational changes relative to unliganded HDAC6 (PDB 5EEM; root-mean-square de-
viation (rmsd) = 0.16–0.17 Å for 290–305 Ca atoms).  
  In the crystal structure of the HDAC6–phenylhydroxamate 1 complex determined at 1.62 
Å resolution, the inhibitor hydroxamate group adopts canonical bidentate Zn2+ coordination, 
forming a 5-membered ring chelate complex with Zn2+---O distances of 2.0 Å and 2.4 Å for the 
N–O– and C=O groups, respectively (Figure 5.2a). This coordination geometry was first observed 
in the binding of hydroxamate inhibitors to the Zn2+ hydrolase thermolysin.137 In the HDAC6 
active site, the hydroxamate oxyanion, NH group, and C=O group also form hydrogen bonds with 
H573, H574, and Y745, respectively (intermolecular distances are recorded in Table 5.2). The 
phenyl ring of the inhibitor is firmly nestled in an aromatic crevice formed by the side chains of 
F563 and F643; the phenyl ring of the inhibitor is offset so that the partial positive charges of its 
ring hydrogen atoms interact with the partial negative charges of the ring p electrons of F583 and 
F643. The dihedral angle between the inhibitor phenyl ring and the hydroxamate moiety is twisted 
34˚ away from planarity.  
  The crystal structure of the HDAC6–cyclohexenylhydroxamate 2 complex determined at 
1.24 Å resolution similarly reveals bidentate hydroxamate-Zn2+ coordination, with Zn2+---O dis-
tances of 2.0 Å and 2.2 Å for the ionized hydroxyl and carbonyl groups, respectively (Figure 5.2b). 
Hydrogen bond interactions with the Zn2+-bound hydroxamate are similar to those observed for  
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Figure 5.2 | Polder omit maps for capless cyclohydroxamates bound to HDAC6 
Polder omit maps (green) contoured at 4.0s for inhibitors (a) 1, (b) 2, (c) 3, and (d) 4 bound to 
HDAC6. Atoms are color-coded as follows: C = orange (inhibitor) or light blue (HDAC6), N = 
blue, O = red, Zn2+ = gray sphere. Metal coordination and hydrogen bond interactions are indicated 
by solid and dashed black lines, respectively.  
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Table 4.2 | Average interatomic distances in HDAC6-cyclohydroxamate complexes (Å) 
Interatomic 
Measurement 
Inhibitor 
1 2 3 4 
C=O---Zn2+ 2.4 2.2 2.2 2.4 
N–O–---Zn2+ 2.0 2.0 2.1 2.0 
N---N(H574) 2.7 2.6 2.8 2.6 
O–---N(H573) 2.8 2.7 2.6 2.6 
C=O---O(Y745) 2.4 2.6 2.5 2.4 
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phenylhydroxamate 1 (Table 5.2). The cyclohexenyl ring of the inhibitor is bound such that the 
olefin moiety is firmly nestled in the F583-F643 aromatic crevice. The dihedral angle between the 
olefin moiety and the hydroxamate is twisted 18˚ away from planarity. 
  The crystal structure of the HDAC6–cyclohexylhydroxamate 3 complex determined at 
2.03 Å resolution reveals nearly perfect bidentate hydroxamate-Zn2+ coordination, with Zn2+---O 
distances of 2.1 Å and 2.2 Å for the ionized hydroxyl and carbonyl groups, respectively (Figure 
5.2c). Hydrogen bond interactions with the Zn2+-bound hydroxamate are similar to those observed 
for phenylhydroxamate (Table 5.2). The cyclohexyl group adopts a chair conformation and packs 
between the side chains of F583 and F643. The dihedral angle between the adjacent C-C bond 
in the cyclohexyl ring and the hydroxamate is twisted 8˚ away from planarity. 
  Finally, the crystal structure of the HDAC6–cyclopentenylhydroxamate 4 complex deter-
mined at 1.70 Å resolution reveals canonical bidentate hydroxamate-Zn2+ coordination geometry 
with Zn2+---O distances of 2.0 Å and 2.4 Å for the ionized hydroxyl and carbonyl groups, respec-
tively (Figure 5.2d). Hydrogen bond interactions with the Zn2+-bound hydroxamate are similar to 
those observed for phenylhydroxamate (Table 5.2). The cyclopentenyl ring of the inhibitor is 
bound such that the olefin moiety is also firmly nestled in the F583-F643 aromatic crevice. The 
cyclopentenyl-hydroxamate dihedral angle is twisted 26˚ away from planarity. 
Three interesting structural features emerge from analysis of the binding modes of capless 
inhibitors 1–4. First, each inhibitor binds with its hydroxamate group coordinated to Zn2+ with 
canonical bidentate geometry. Notably, many HDAC6-selective inhibitors such as HPB (Figure 
5.3) contain a core phenylhydroxamate moiety as represented by inhibitor 1. Depending on the 
capping group attached to the phenylhydroxamate, bidentate or monodentate hydroxamate coor-
dination to the catalytic Zn2+ ion will result, with the monodentate coordination mode being only  
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Figure 5.3 | Superposition of HPB linker with phenylhydroxamate (1) 
Chemical structure of HPB and stereoview of the superposition of the experimentally determined 
structure of the HDAC6–HPB complex (PDB 5WGK; blue) with a model of HPB in the same 
conformation with its phenylhydroxamate moiety superimposed with that observed in the 
HDAC6–1 complex. Phenylhydroxamate 1 is shown in yellow while the modeled HPB cap is 
shown in orange.  
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0.5 kcal/mol less stable than the bidentate coordination mode (Figure 5.1).142 For example, HPB131 
exhibits monodentate Zn2+ coordination;142 least-squares superposition of the crystal structures of 
the HDAC6–HPB (PDB ID: 5WGK) and HDAC6–1 complexes (rmsd = 0.12 over 283 Ca 
atoms) reveals slight differences in the orientation of the aromatic ring (Figure 5.3). Specifically, 
the aromatic ring of the capless phenylhydroxamate 1 is tilted by approximately 10˚, which allows 
a closer approach to the catalytic Zn2+ ion, which in turn enables bidentate hydroxamate-Zn2+ 
coordination.  
Superposition of the HPB phenylhydroxamate moiety with compound 1 demonstrates 
that no particular interaction of the capping group appears to govern the hydroxamate-Zn2+ bind-
ing mode. If HPB were tilted so as to superimpose its phenylhydroxamate moiety with that of 
capless phenylhydroxamate 1 in the HDAC6–1 complex (Figure 5.3), the bulky capping group 
would not clash with any active site residues. Thus, it is not clear how the geometry of hydrox-
amate-Zn2+ coordination might be influenced by interactions of the capping group of HPB.  
Second, while compounds 1, 2, and 4 contain C=C bonds potentially capable of conjuga-
tion with the p system of the hydroxamate moiety, their respective C=C–C=O dihedral angles are 
distorted 36˚, 11˚, and 46˚ from planarity. These values lie within the broad distribution observed 
for similar compounds retrieved from the Cambridge Structural Database (Figure 5.4), so there 
does not appear to be a strong energetic driving force to maintain planarity of the extended p 
system.  
Finally, the binding orientations of cyclohexenylhydroxamate 2 and cyclopentenylhydrox-
amate 4 unambiguously place the C=C bond in the F583-F643 aromatic crevice, as also observed 
for the aromatic ring of phenylhydroxamate 1. Therefore, this aromatic crevice preferentially ac-
commodates a planar olefin moiety contained in a 6- or 5-membered ring, including a 6-memb- 
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Figure 5.4 | Dihedral angles in conjugated aromatic hydroxamic acids 
Deviations from planarity observed in conjugated aromatic hydroxamic acids. A total of 145 inde-
pendent examples were found in 87 structures retrieved from the Cambridge Structural Database. 
The search query is shown as an inset structure and the angle measured is highlighted in yellow.  
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-ered aromatic ring. The chair-conformation 6-membered ring of cyclohexylhydroxamate 3 is not 
as readily accommodated based on previously measured148 IC50 values (Figure 5.5). Of the linker 
groups represented in the current study, it appears that the cyclohexenyl group of inhibitor 2 would 
be most ideal for further derivatization to enhance HDAC6 selectivity. 
5.3.2 – Isothermal Titration Calorimetry (ITC) 
To gain additional insight on the molecular basis of affinity and selectivity for inhibitor 
binding to HDAC6, we studied the thermodynamics of enzyme-inhibitor association using ITC. 
We also studied inhibitor binding to the representative class I isozyme HDAC8 using ITC to 
evaluate the extent of HDAC6 selectivity against class I HDACs. Titrations of inhibitors 1–4 
against HDAC6 and HDAC8 reveal that the ITC-derived dissociation constants (Kd) generally 
correlate (within a factor of 4) with previously measured148 IC50 values for each enzyme-inhibitor 
complex (Figure 5.5).   
  The selectivity of the best capless inhibitors for HDAC6 compared with HDAC8 appears 
to be rooted in a substantial and favorable entropic gain for HDAC6 association. Specifically, the 
–TDS term is negative and favorable for the binding of inhibitors 1–4 to HDAC6, whereas –TDS 
is positive and unfavorable for the binding of these inhibitors to HDAC8 with the exception of 
compound 3 (Figure 5.5, Figure 5.6). In other words, the binding of cycloalkenyl hydroxamates 
1, 2, and 4 to HDAC6 is accompanied by a substantial entropy gain, whereas the binding of these 
cycloalkenyl hydroxamates to HDAC8 is accompanied by an entropic loss. The outlier is the cy-
cloalkane hydroxamate 3, which exhibits a modest and favorable entropy of binding to HDAC8; 
however, this compound also exhibits the weakest affinities for HDAC8 and HDAC6 and the 
poorest selectivity for HDAC6 (Figure 5.5). Thus, planar cycloalkenyl hydroxamates yield optimal  
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Figure 5.5 | Selectivity of hydroxamate inhibitors for HDAC6 versus HDAC8 
IC50 values compared with Kd values derived from ITC measurements for "capless" HDAC6-se-
lective inhibitors 1–4 and "capped" inhibitors SAHA, Ricolinostat, and HPB. IC50 values are ab-
stracted from ref. 46 (1–4), ref. 151 (SAHA), ref. 132 (Ricolinostat), and ref. 131 (HPB). Kd data 
derive from isothermal titration calorimetry.  
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Figure 5.6 | Thermodynamic values for the binding of hydroxamate inhibitors 
Thermodynamic values derived from ITC measurements for the binding of inhibitors 1–4, SAHA, 
Ricolinostat (R’stat), and HPB to HDAC6 CD2 (top) and HDAC8 (bottom).  
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affinities and HDAC6/HDAC8 selectivities of 16-fold up to 313-fold, and binding entropy ap-
pears to drive this selectivity.  
Presuming identical conformations for the binding of compounds 1–4 in the active sites 
of other HDAC isozymes, we speculate that differences in the entropy of inhibitor binding to 
HDAC6 and HDAC8 could be rooted in differences in conformational entropy and/or desolva-
tion entropy involving the F583-F643 aromatic crevice of HDAC6, which is conserved in 
HDAC8 as F152 and F208. Crystal structures of the class I isozymes HDAC1, HDAC2, and 
HDAC3,44–46 and the class IIa isozymes HDAC4 and HDAC7,47,50 reveal that this aromatic crev-
ice is similarly conserved. However, structural comparisons of all isozymes reveal that relative to 
HDAC6, the aromatic crevice is approximately 1 Å wider in class I and class IIa HDACs. More-
over, there is evidence of conformational flexibility for one wall of this crevice: upon the binding 
of a bulky phenylhydroxamate inhibitor to HDAC8, the side chain of F152 rotates to adopt a 
conformation similar to that of the corresponding phenylalanine residue, F679, in the aromatic 
crevice of HDAC7.50,149 It is conceivable that inhibitor binding rigidifies the conformation of the 
aromatic crevice in HDAC8, thereby accounting for a conformational entropy loss. This possibil-
ity may also extend to other class I and class IIa HDACs. If the narrower aromatic crevice of 
HDAC6 is more rigid, then inhibitor binding would not incur a conformational entropic cost and 
the favorable entropy gain from active site desolvation could dominate the binding thermodynam-
ics.   
  To assess the influence of a capping group on the thermodynamics of HDAC6/HDAC8 
selectivity, we additionally studied the binding of the phenylhydroxamate derivative HPB,131 the 
aliphatic hydroxamate inhibitor Ricolinostat,132 and the aliphatic hydroxamate inhibitor suberoy-
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lanilide hydroxamic acid (SAHA).150 The ITC-derived inhibitor dissociation constants (Kd) gen-
erally correlated with IC50 values for HDAC8 (within a factor of 4), but those for HDAC6 do not 
(7–32-fold variations are observed). Regardless, each of these inhibitors exhibits selectivity for 
binding to HDAC6 compared with HDAC8 (Figure 5.5),131,132,151 and selectivity is characterized 
by a favorable entropic gain upon binding to HDAC6 and an unfavorable entropic loss upon 
binding to HDAC8 (Figure 5.5, Figure 5.6). The results for HPB binding indicate that the 
HDAC6 selectivity inherent in the binding of capless cycloalkenyl hydroxamate inhibitors is gen-
erally maintained, but no inhibitor studied here surpasses the 313-fold thermodynamic selectivity 
based on Kd values measured for cyclohexenylhydroxamate 2 (Figure 5.5). Even so, it is interesting 
that favorable binding entropy to HDAC6 is not exclusive to inhibitors bearing aromatic or cy-
cloalkenyl linker groups, but also includes inhibitors bearing aliphatic linker groups such as Rico-
linostat and SAHA. 
  
117 
 
5.4 | Conclusions 
The binding thermodynamics of compounds 1–4 to HDAC6 versus HDAC8 reflect that 
entropy is a key contributor to HDAC6-inhibitor binding selectivity; moreover, compounds bear-
ing a single double bond in the ring adjacent to the hydroxamate moiety are more selective for 
HDAC6 than their aromatic or saturated capless counterparts. In particular, cycloalkenyl hydrox-
amate 2 exhibits 313-fold selective tighter binding to HDAC6 compared with HDAC8 (Figure 
5.5).  
The olefin moiety of 2 is preferentially accommodated in the F583-F643 aromatic crevice 
of HDAC6. It is not clear, however, whether the entropic favorability contributing to HDAC6 
selectivity is associated with binding in this crevice, since these aromatic residues are also conserved 
in HDAC8 as well as other class I HDAC isozymes. However, the active site of HDAC8 is 
slightly larger than that of HDAC6, with an 8 Å separation between F152 and F208 in the aro-
matic crevice, compared with the 7 Å separation between F583 and F643 in the aromatic crevice 
of HDAC6. Additionally, F152 in HDAC8 exhibits conformational flexibility in complex with a 
bulky phenylhydroxamate inhibitor, which expands the F152-F208 separation to 8.5 Å.149 Possi-
bly, the conformational flexibility of the aromatic crevice in HDAC8 contributes to the generally 
unfavorable entropy of inhibitor binding evident in Figure 5.6. In HDAC6, there is no evidence 
for conformational flexibility in the aromatic crevice, so the favorable entropy of inhibitor binding 
may be linked solely to desolvation.  
Notably, the F583-F643 aromatic crevice of HDAC6 preferentially accommodates planar 
olefins, and this crevice does not accommodate the chair-conformation cyclohexyl hydroxamate 3 
as readily. This inhibitor exhibits the lowest inhibitory potency, affinity, and HDAC6 selectivity 
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among the compounds studied (Figure 5.5). Thus, hydroxamate inhibitor designs using core cy-
clohexenyl hydroxamate 2 would represent an ideal starting point for the design of HDAC6 in-
hibitors with high affinity and selectivity.  
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Chapter 6 | HDAC6-Selective Inhibition by Mercaptoacetamides 
Work presented here is reprinted from Porter, N.J.; Shen, S.; Barinka, C.; Kozikowski, A.P.; 
Christianson, D.W. ACS Med. Chem. Lett. 2018, 8, 879-884. 
 
6.1 | Introduction 
  Including those discussed chapters 3, 4, and 5, nearly all of the inhibitors that have been 
structurally characterized in complex with HDAC6 bear hydroxamate Zn2+-binding groups. 
However, the genotoxicity associated with the hydroxamate group, such as that of the classic 
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA,150 formulated as the cancer chemo-
therapy drug Vorinostat29), argues against the use of a hydroxamate-containing inhibitor as a long-
term therapy for diseases other than cancer.91,152 The chemical basis of genotoxicity derives from 
the Lossen rearrangement (Figure 6.1), which yields a reactive isocyanate intermediate capable of 
covalently modifying cellular components.91 This undesirable chemistry has motivated the search 
for HDAC inhibitors with alternative zinc-binding groups. 
  Notably, inhibitors bearing mercaptoacetamide zinc-binding groups are not genotoxic and 
exhibit superior neuroprotective properties.153 Moreover, certain mercaptoacetamide inhibitors ex-
hibit nanomolar affinity and better that 103-fold selectivity against HDAC6.154,155 Preceding the 
work presented here, the structural basis for HDAC6 affinity and selectivity not been defined. 
  To structurally characterize the underpinnings of this selectivity, we determined the 1.85 
Å resolution structure of complex between mercaptoacetamide inhibitor N-(5-(5,6-dichloro-
1H0indol-1-yl)pentyl)-2-mercaptoacetamide (MCA; Figure 6.1)155 and catalytic domain 2 from 
Danio rerio (zebrafish). MCA exhibits 240-fold selectivity for the inhibition of HDAC6 over 
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HDAC8. The work detailed here describes how mercaptoacetamides can be used to exploit a 
subtle chemical difference between HDAC isozymes which contributes to their function as 
HDAC6-selective inhibitors. 
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Figure 6.1 | Mercaptoacetamide selectivity and the hydroxamate Lossen rearrangement 
(a) Structures and selectivity data for SAHA131 and MCA alongside (b) the mechanism for the 
Lossen rearrangement as potentially catalyzed by the Zn2+ ion in the HDAC active site.  
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6.2 | Materials and Methods 
6.2.1 - Reagents.  
In general, chemicals used in buffers and crystallization were purchased from Fisher, Mil-
lipore Sigma, or Hampton Research and used without further purification. The inhibitor MCA 
was synthesized according to published procedures.155 
6.2.2 - Expression and purification of HDAC6 and HDAC8 for assay.  
Full-length wild-type human HDAC6 (residues 1-1215; UniProtKB - Q9UBN7) and 
HDAC8 (residues 1-377; UniProtKB - Q9BY41) were prepared essentially as described previ-
ously.23,156 Briefly, expression plasmids encoding individual HDACs flanked by the N-terminal 
Strep-FLAG-HALO tag were constructed using the Gateway-based cloning protocol. Recombi-
nant proteins were heterologously expressed in HEK-293/T17 following the polyethylenimine-
mediated transient transfection. Three days after transfection cells were harvested, lysed in a lysis 
buffer [50 mM Tris (pH 8.0), 150 mM NaCl, 10 mM KCl, 2 mM MgCl2, 10% glycerol, and 
0.2% Igepal-630] supplemented with benzonase (2 U/ml; Merck, Darmstadt, Germany) and a 
cocktail of protease inhibitors (Roche, Basel, Switzerland). The cell lysate was cleared by centrif-
ugation (40,000xg for 30 mins at 4°C) and the supernatant was loaded onto a Strep-Tactin column 
(IBA, Gottingen, Germany) previously equilibrated in the lysis buffer. Following extensive wash-
ing with the lysis buffer, fusion proteins were eluted with the elution buffer supplemented with 3 
mM desthiobiotin. The N-terminal tag was removed by the addition of the 1:20 (w/w) TEV 
protease overnight at 4°C and proteins further purified by size exclusion chromatography using 
the Superdex 16/600 HR200 column with 30 mM HEPES (pH 7.4), 140 mM NaCl, 10 mM 
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KCl, 3% glycerol, and 0.25 mM TCEP, as a mobile phase. Proteins were concentrated to approx-
imately 1 mg/mL and aliquots were flash frozen in liquid nitrogen and stored at -80°C until fur-
ther use. Final HDAC preparations have >95% purity as determined by SDS-PAGE. 
6.2.3 - Inhibitory potencies against HDAC6 and HDAC8.  
The inhibition constants were determined using a fluorogenic assay essentially as described 
previously.156 Briefly, the inhibitor MCA was preincubated with optimized concentrations of in-
dividual HDACs at 37°C for 15 min in the assay buffer [50 mM HEPES (pH 7.4), 140 mM 
NaCl, 10 mM KCl, 1 mg/mL bovine serum albumin, and 1 mM TCEP] in the total volume of 
20 µL in 384-well plates. The deacetylation reaction was started by addition of 10 µL of acetyl-
Gly-Ala-[acetyl-Lys]-AMC (HDAC6) or Boc-[trifluoroacetyl-Lys]-AMC (HDAC8) to a final 
concentration of 10 µM. Following a 30-min incubation at 37°C, the reaction was stopped by the 
addition of trypsin solution (10 µL; 2 mg/mL) and after 15-min incubation at 37°C, a fluorescence 
signal of released aminomethylcoumarin was quantified using a CLARIOstar fluorimeter with 
excitation/emission wavelengths set at 365/440 nm, respectively. Data were fit using the 
GraphPad Prism software and IC50 values were calculated by non-linear regression analysis. The 
inhibitor and enzyme-free controls were defined as 100% and 0% HDAC activity, respectively. 
6.2.4 - Expression and purification of HDAC6 for crystallization.  
HDAC6 catalytic domain 2 from Danio rerio (henceforth simply "HDAC6") was recom-
binantly expressed using the MBP-TEV-z6CD2-pET28a(+) vector and purified as previously de-
scribed with minor modification.48,142 Briefly, HDAC6 was expressed using Escherichia coli strain 
BL21 (DE3) (Stratagene) in 2x YT medium under the selection of 50 mg/L kanamycin. Expres-
sion was induced by 100 µM isopropyl b-L-1-thiogalactopyranoside (IPTG; Gold Biotechnology) 
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and 200 µM ZnCl2 at 16 ˚C. Cells were collected by centrifugation and stored at -80 ˚C prior to 
purification. 
  Pellets were thawed and resuspended in lysis buffer [50 mM 4-(2-hydroxyethyl)-1-piper-
azine-ethanesulfonic acid (HEPES; pH 7.5), 300 mM KCl, 10% glycerol (v/v), 1 mM tris(2-
carboxyethyl)phosphine (TCEP)] and lysed by sonication. Lysate was clarified by centrifugation 
at 33,000g for 1 hour at 4 ˚C. The supernatant was applied to an amylose column (New England 
BioLabs) and protein was eluted using 10 mM maltose. Protein was digested using recombinant 
His-TEV protease overnight at 4 ˚C while dialyzing in purification buffer supplemented with 20 
mM imidazole. The digest was applied to equilibrated Ni-NTA resin (Qiagen) to remove His-
MBP and His-TEV, which were subsequently eluted with a 0–400 mM imidazole gradient in 
purification buffer. The HDAC6-containing fractions were concentrated to <10 mL over a 10-
kD molecular weight cut-off filter unit (Millipore) and applied to a HiLoad Superdex 200pg col-
umn in size exclusion buffer [50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM 
TCEP]. Fractions containing pure HDAC6 were identified using SDS-PAGE, pooled, and con-
centrated to 14–20 mg/mL. Protein was flash cooled in liquid nitrogen and stored at -80 ˚C prior 
to usage. 
For cocrystallization of the HDAC6–MCA complex, a 3.5 µL drop of protein solution [10 
mg/mL HDAC6, 50 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol (v/v), 1 mM TCEP, 
saturated MCA (~1 mM), and 5% dimethyl sulfoxide (DMSO) (v/v)] was added to a 4.0 µL drop 
of precipitant solution [0.04 M citrate/0.06 M BisTris propane (pH 6.4) and 20% (w/v) PEG 
3,350] and equilibrated against a 500 µL reservoir of precipitant solution. Rhomboid plate-like 
crystals appeared within 2 days. Crystals were soaked in a cryoprotectant solution consisting of 
mother liquor supplemented with 20% ethylene glycol prior to flash-cooling in liquid nitrogen. 
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6.2.5 - Crystallographic data collection and structure determination.  
X-ray diffraction data were collected from crystals on beamline 24-ID-E at the Advanced 
Photon Source (APS), Argonne National Laboratory (HDAC6–TSA complex). Data were in-
dexed and integrated using iMosflm103 and scaled using Aimless in the CCP4 program suite.104 
Data collection statistics are recorded in Table S1. 
  The crystal structure was solved by molecular replacement using the atomic coordinates of 
unliganded HDAC6 (PDB 5EEM)48 as a search model for rotation and translation function cal-
culations using the program Phaser.105 Atomic models were constructed using the graphics pro-
gram Coot106 and crystallographic structure refinement was performed using Phenix.107 Inhibitor 
molecules in monomers A and B in the asymmetric unit were added in the later stages of refine-
ment. Occasionally, maps displayed spurious electron density peaks that could not be satisfactorily 
modeled by ordered solvent, in which case were left uninterpreted. The overall quality of each 
model was assessed using MolProbity108 and PROCHECK.109 Final refinement statistics are rec-
orded in Table 6.1. 
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Table 6.1 | Structural statistics for the HDAC6–MCA complex 
HDAC6–MCA 
Unit Cell 
Space group C2 
a, b, c (Å) 159.0, 46.5, 96.4 
a, b, g (˚) 90.0, 119.2, 90.0 
Data Collection 
Wavelength (Å) 0.97917 
Resolution (Å) 84.16–1.85 
Total / unique no. of reflections 168.669 / 52,293 
Rmergea,b 0.090 (0.627) 
Rpima,c 0.065 (0.440) 
CC1/2a,d 0.991 (0.642) 
I/s(I)a 7.5 (2.3) 
Redundancya 3.2 (3.3) 
Completeness (%)a 98.9 (99.6) 
Refinement 
No. of reflections used in re-
finement / test set 52,282 / 5,227 
Rworka,e 0.190 (0.279) 
Rfreea,e 0.226 (0.319) 
No. of nonhydrogen atoms:  
protein 5539 
ligand 79 
solvent 324 
Average B-factors (Å2)  
protein 24 
ligand 34 
solvent 29 
Root-mean-square deviation 
from ideal geometry  
bonds (Å) 0.003 
angles (˚) 0.7 
Ramachandran plot (%)f  
favored 97.2 
allowed 2.8 
PDB accession code 6MR5 
aValues in parentheses refer to data in the highest shell. bRmerge = ∑hkl∑i|Ii,hkl − ⟨I⟩hkl|/∑hkl∑i Ii,hkl, where ⟨I⟩hkl is the average 
intensity calculated for reflection hkl from replicate measurements. cRp.i.m.= (∑hkl(1/(N-1))1/2∑i|Ii,hkl − ⟨I⟩hkl|)/∑hkl∑i Ii,hkl, 
where ⟨I⟩hkl is the average intensity calculated for reflection hkl from replicate measurements and N is the number of 
reflections dPearson correlation coefficient between random half-datasets. eRwork = ∑||Fo| − |Fc||/∑|Fo| for reflections 
contained in the working set. |Fo| and |Fc| are the observed and calculated structure factor amplitudes, respectively. Rfree 
is calculated using the same expression for reflections contained in the test set held aside during refinement. fCalculated 
with PROCHECK.109  
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6.3 | Results and Discussion 
  The 1.85 Å resolution structure of the HDAC6-MCA complex was determined to char-
acterize isozyme-selective HDAC inhibition by an inhibitor bearing a non-hydroxamate warhead. 
Crystallographic refinement converged smoothly to Rwork/Rfree = 0.190/0.226; data collection and 
refinement statistics are recorded in Table 6.1. The overall structure of the polypeptide chain in 
the HDAC6-MCA complex is essentially identical to that in the unliganded enzyme (root-mean-
square deviation = 0.2 Å over 292 Ca atoms), indicating that no major structural rearrangements 
are required for the binding of MCA. 
An electron density map showing the bound inhibitor is presented in Figure 6.2. The thiol 
group of MCA is presumably ionized to the negatively charged thiolate and coordinates to the 
active site Zn2+ ion such that the overall metal coordination geometry is slightly distorted tetrahe-
dral, with ligand–Zn2+–ligand angles ranging 94˚–127˚ across both monomers in the asymmetric 
unit of the crystal; metal coordination geometry deviates from ideal tetrahedral geometry by an 
average deviation of 10 ± 5˚ for ligand-Zn2+-ligand bond angles. For monomers A and B, the Zn2+-
--S separations are 2.3 Å, the C–S–Zn2+ angles are 114˚ and 120˚, and the C–C–S–Zn2+ dihedral 
angles are 14˚ and 2˚, respectively. Apart from the cisoid C–C–S–Zn2+ dihedral angle, the Zn2+ 
coordination geometry is ideal as outlined for thiolate-metal coordination interactions in refined 
protein structures.157 In comparison, the Zn2+-bound thiolate group of the cyclic depsipeptide Lar-
gazole thiol exhibits similar coordination geometry except for a more favorable C–C–S–Zn2+ di-
hedral angle of 92˚ in its complex with HDAC8.92  
The zinc-bound thiolate group of MCA accepts a hydrogen bond from the side chain of 
H573 (Ne573---S separation = 3.1 Å), which in turn donates a hydrogen bond to D610 (Nd573--- 
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Figure 6.2 | Binding of MCA to HDAC6 catalytic domain 2 
(a) Polder omit map (4.0s; green mesh) for MCA (orange) bound to HDAC6 (blue). Hydrogen 
bond and metal-coordination interactions are shown as dashed and solid lines, respectively. The 
active site zinc ion is represented as a gray sphere. (b) Schematic representation of active site inter-
actions for MCA bound to HDAC6.  
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O610 separation = 2.8 Å), thus confirming that the side chain of H573 is in the positively charged 
imidazolium state. H573 is the first histidine in a tandem pair found in all HDAC active sites. 
Similar interactions are observed in the crystal structure of Schistosoma mansoni HDAC8 
(SmHDAC8; 42% identity with human HDAC8) complexed with a mercaptoacetamide analog 
of SAHA, in which the Zn2+-bound thiolate group accepts a hydrogen bond from H141 (average 
Ne141---S separation for monomers A–D = 3.3 Å) (Figure 3).158  
In the HDAC6-MCA complex, the mercaptoacetamide carbonyl oxygen accepts a hydro-
gen bond from the phenolic hydroxyl group of Y745 (O745---O separation = 2.4 Å). This interac-
tion mimics the role of Y745 in polarizing the scissile carbonyl group of acetyl-L-lysine.48 How-
ever, the carbonyl oxygen of MCA is 2.0 Å away from the Zn2+ coordination site ordinarily re-
quired for substrate binding, such that the Zn2+---O separation is 3.4 Å. Since both metal coor-
dination and hydrogen bond interactions are required to activate the scissile amide group for hy-
drolysis, the amide group of the mercaptoacetamide is rendered chemically inert through its bind-
ing geometry in the HDAC6 active site.  
The mercaptoacetamide NH group donates a hydrogen bond to Ne of H574 (Ne574---N 
separation = 3.2 Å and 3.0 Å in monomers A and B, respectively), which requires that the side 
chain of H574 is in the neutral imidazole form. This is the second histidine in the tandem pair; 
intriguingly, the corresponding interaction with the second histidine, H142, in the mercaptoa-
cetamide complex with SmHDAC8 is too long for hydrogen bonding (Ne---N separations range 
3.5–4.0 Å in monomers A–D). Structures of mercaptoacetamide inhibitors complexes with 
HDAC6 and SmHDAC8 are compared in Figure 6.3. The lack of a hydrogen bond with H142 
in the SmHDAC8-mercaptoacetamide complex may be due to the side chain of H142 being pro-
tonated as the positively charged imidazolium cation.  
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Figure 6.3 | Comparison of mercaptoacetamide binding to HDAC6 and HDAC8 
Structures of (a) S. mansoni HDAC8 (dark red; PDB ID 4CQF) complexed with a mercaptoa-
cetamide analog of SAHA (yellow) and (b) the HDAC6-MCA complex (colors match Figure 2) 
showing interactions in the active site of each enzyme. Hydrogen bond and metal-coordination 
interactions are shown as dashed and solid lines respectively.  
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The role of the second histidine in the tandem pair as a hydrogen bond acceptor, requiring 
a neutral imidazole side chain, is similarly required for the binding of hydroxamate inhibitors with 
bidentate Zn2+ coordination geometry. In bidentate hydroxamate complexes with HDAC6, the 
hydroxamate NH group donates a hydrogen bond to H574.48,142,159 The same is true in human 
HDAC8-hydroxamate inhibitor complexes, where the hydroxamate NH group donates a hydro-
gen bond to H143.51,72 Thus, the mercaptoacetamide moiety is, in effect, a functional mimic of a 
hydroxamate group in terms of its ability to make an identical constellation of metal coordination 
and hydrogen bond interactions in the HDAC6 active site. Even better, the mercaptoacetamide 
moiety is not mutagenic since it is not subject to degradation via the Lossen rearrangement. 
Why, then, does the mercaptoacetamide exhibit different binding interactions in the active 
site of SmHDAC8, lacking a hydrogen bond with the second active site histidine in the tandem 
pair? The mercaptoacetamide moiety clearly does not serve as a functional mimic of a hydroxamate 
group in binding to HDAC8. This difference likely contributes to weaker inhibition of class I 
HDAC isozymes by mercaptoacetamides.154,155 Structural comparisons of HDAC6, SmHDAC8, 
and human HDAC8 reveal that the second histidine is in a different electrostatic environment in 
each isozyme. In SmHDAC8 and human HDAC8, this histidine (H142 in SmHDAC8, H143 
in human HDAC8) donates a hydrogen bond to a negatively charged carboxylate side chain 
(D191 in SmHDAC8, D183 in human HDAC8), which elevates the histidine pKa.77 In contrast, 
the corresponding histidine in HDAC6, H574, donates a hydrogen bond to the neutral carbox-
amide side chain of N617, which would elevate the pKa of H574, but not as much as would result 
if the hydrogen bond were made with a negatively charged carboxylate. Accordingly, H574 of 
HDAC6 is less basic than H142/H143 of SmHDAC8/human HDAC8. Consequently, H142 of 
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SmHDAC8 and H143 of human HDAC8 are more likely to be protonated than H574 of 
HDAC6 at a given pH. 
Differences in the basicity of the second histidine in the tandem pair also have implications 
for catalysis. In human HDAC8, enzymological and structural studies indicate that the second 
histidine, H143, functions as a single general base-general acid.77 Although similar enzymological 
studies have not yet been performed with HDAC6, deletion of the second histidine by mutagen-
esis in the H574A variant enables the crystallization and structure determination of an intact en-
zyme-substrate complex as the tetrahedral intermediate in the catalytic mechanism.48 This obser-
vation implies that the general base functionality in the active site of H574A HDAC6 is preserved 
– formation of the tetrahedral intermediate requires a sufficiently nucleophilic water molecule ac-
tivated by Zn2+ coordination and a general base. Thus, the remaining active site histidine, H573 
in H574A HDAC6, might function as the general base in this isozyme. H574 must serve as the 
general acid, since its deletion leads to the trapped intermediate. The tetrahedral intermediate of 
amide hydrolysis cannot collapse without a proton donor to the leaving amino group, so the dele-
tion of the general acid in H574A HDAC6 results in the formation of the tetrahedral intermediate 
as a dead-end complex.  
Other aspects of MCA binding to HDAC6 contribute to its selectivity as well. The ali-
phatic linker packs into the aromatic groove in the substrate binding cleft with distances of 3.7 Å 
and 3.5 Å to the phenyl rings of F583 and F643 respectively. The capping group of the inhibitor 
is situated within the previously characterized L1 loop pocket, an interaction that confers HDAC6 
selectivity.159 The chlorine atoms of the dichloroindole capping group pack against the side chains 
of H463 and P464. Additionally, the capping group of the inhibitor bound to monomer A packs 
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against R636, D638, and F642 of monomer B. Meanwhile, the molecule bound to monomer B 
forms lattice contacts against D460 and H462 of monomer A. 
It is worthwhile to note that thiol-containing drug candidates such as MCA can be subject 
to oxidation chemistry or reaction with an unintended electrophile in vivo, which could compro-
mise their inhibitory function. The thiol-containing HDAC inhibitors Romidepsin and Largazole 
evolved to exist as thioester and disulfide-linked prodrugs, respectively.37 Romidepsin is activated 
by reduction of its internal disulfide linkage to yield the active inhibitor Romidepsin thiol, and 
Largazole is activated by hydrolysis of its thioester linkage to yield Largazole thiol. That being 
said, HDAC6 is localized in the cell cytosol,122 which is highly reducing, so this would favor the 
free thiol form of such inhibitors, including MCA. Moreover, there is precedent for the efficacy 
of a thiol-functionalized drug as exemplified by Captopril, which contains a thiol group targeting 
Zn2+ coordination in the active site of angiotensin converting enzyme.160,161   
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6.4 | Conclusion 
In summary, the present study highlights a chemical difference in the binding of mercap-
toacetamides and hydroxamates to HDAC6 and HDAC8, specifically with regard to interactions 
with the tandem histidine pair in the active site. While each class of inhibitor contains a functional 
group that directly coordinates to Zn2+ (C-S– and N-O–, respectively), interactions with nearby 
active site residues differ. When bound to either enzyme, the hydroxamate N–O– group interacts 
with both histidine side chains. However, mercaptoacetamides exhibit different interactions in 
HDAC6 and HDAC8, specifically with regard to the second histidine. This highlights the im-
portance of the tandem histidine pair in each of these enzymes – differences in the basicity of the 
second histidine residue can influence inhibitor binding and catalysis, which in turn can be ex-
ploited to enhance inhibitor selectivity. 
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Chapter 7 | Summary & Prospects 
Summary 
 Taken as a whole, the works described in this thesis have advanced our understanding of 
the chemical principles underlying isozyme-selective HDAC inhibition. Discovery of the unusual 
monodentate binding mode exploited by potent HDAC6 inhibitors highlights the shallower nature 
of this enzyme’s active site which can be targeted by employing sterically bulky capping groups. 
One such region of the enzyme surface is a cavity formed by the L1 loop, which is more recessed 
from the active site than in other isozymes and readily accommodates nonpolar moieties. Since the 
entropy of inhibitor binding is generally positive for HDAC6 while the same value is negative for 
HDAC8, it appears that HDAC6 is predisposed to be targeted by simple hydroxamate inhibitors. 
Characterization of the entropic change upon the binding of future drug leads will help to identify 
scaffolds that best take advantage of this phenomenon. Additionally, differences in the hydrogen 
bonding network for mercaptoacetamide inhibitors bound to HDAC6 and HDAC8 highlight sub-
tle mechanistic differences that may be exploitable in the engineering of better-targeted therapeu-
tics. All in all, this work has contributed to the foundation upon which future efforts toward the 
selective inhibition of HDACs can be built. 
 
Future Directions 
 Major challenges still exist in pursuit of selective HDAC inhibition. The pursuit of potent 
and selective nonhydroxamate zinc binding groups is vital to the development of therapeutics that 
are amenable to long-term treatments. While mercaptoacetamide-based inhibitors discussed here 
have certainly been shown to be neuroprotective in a mouse model,155 the thiol zinc binding group 
suffers from certain challenges due to its nucleophilicity and susceptibility to redox chemistry within 
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the cell. As a result, further exploration of potential inhibitory warheads is required. With the dis-
covery that irreversible class I HDAC inhibition by a,b-epoxyketones (such as that found in 
trapoxin A) is dependent on sterics rather than a long-presumed covalent modification, it is possible 
that a,b-cyclopropyl- or cyclobutylketones may serve as viable pharmacophores. The privileged 
status of cyclopropyl groups in many pharmaceuticals makes this a particularly attractive line of 
inquiry.162 Additionally, since HDAC inhibitors are currently used in the clinic to sensitize cancers 
to other therapeutics, the design of dual-faced inhibitors (i.e. a single-molecule that inhibits mul-
tiple pathways in combinatorial therapies) may assist in the development of inhibitors for the treat-
ment of specific conditions in which multiple biological processes have become dysregulated. The 
validity of this concept has already been demonstrated in the design of RTS-V5, a phenylhydrox-
amate-based HDAC6 inhibitor bearing a proteasome inhibitor as its capping group.146 
 With regard to HDAC function, one of the largest open questions concerns the substrate 
specificity of particular isozymes. In other words, how is the deacetylation of almost 40,000 known 
acetylation sites regulated by less than 20 enzymes? While it is likely that there are enzymes capable 
of lysine deacetylation that remain uncharacterized, it has still been shown that many of the metal-
dependent HDACs are capable of deacetylating several different substrate proteins. It follows that 
factors influencing isozyme-selective inhibition may also play a role in substrate selection by a par-
ticular HDAC. This is evidenced when comparing the structures of the HDAC8-trapoxin A com-
plex, in which an aspartate mimics substrate binding through two hydrogen bonds to the backbone 
around the scissile acetyllysine, and the HDAC6-HC toxin complex, in which an isosteric serine 
makes only a hydrogen bond. This suggests that HDAC6 can better accommodate acetyllysine 
substrate immediately followed by a proline residue, while HDAC8 would require a nonproline 
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residue in this position. Therefore, the determination of structures with other peptidomimetic in-
hibitors will provide information about both inhibition and catalysis in HDAC enzymes. 
To better understand the structural underpinnings of HDAC substrate specificity, it is also 
vital to determine crystal structures between catalytically-inactive HDACs and substrate peptides 
or proteins. An ideal starting place for this work is the complex between HDAC8 and its most 
well-characterized substrate, structural maintenance of chromosomes protein 3 (SMC3). The 
structure of the yeast ortholog of SMC3 has been determined, providing a good starting point for 
the design of a crystallizable construct of the human protein. Due to its broad range of substrates, 
a complex between HDAC8 and a protein substrate would provide valuable insight into the inter-
actions required for identification of a substrate for deacetylation. The general conservation of the 
active site across most metal-dependent HDACs suggests that substrates are selected by interac-
tions at the enzymes surface, rather than at the site of deacetylation. The characterization of specific 
HDAC-substrate pairs may even provide access to pharmaceuticals targeting specific pathways of 
deacetylation. This would represent a major advance in understanding the regulatory pathways em-
ployed at the cellular level for the maintenance of life’s processes. 
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